var title_f13_31_13808="Stepped pharmacotherapy for generalized anxiety disorder";
var content_f13_31_13808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F64594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F64594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Algorithm for stepped pharmacotherapy for generalized anxiety disorder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 515px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cognitive behavioral therapy can be used as an alternative first-line treatment or in combination with medications. The choice between pharmacotherapy and CBT may be based on availability and patient preference.",
"    <div class=\"footnotes\">",
"     * A benzodiazepine such as lorazepam can be used if needed to manage anxiety before the SSRI takes effect.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA 2010; 303:1921.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13808=[""].join("\n");
var outline_f13_31_13808=null;
var title_f13_31_13809="Central spinal cord syndrome PI";
var content_f13_31_13809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Central spinal cord syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 720px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    People with central spinal cord syndrome lose some sensation in the upper part of the body (the shaded part in the drawing). Sometimes they also have weakness in those body parts or trouble moving them.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13809=[""].join("\n");
var outline_f13_31_13809=null;
var title_f13_31_13810="Patient information: Late puberty (The Basics)";
var content_f13_31_13810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16738\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"         Male reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"          Female reproductive anatomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/12/1218\">",
"         Patient information: Acne (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/12/3266\">",
"         Patient information: My child is short (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/1/30738\">",
"         Patient information: Normal sexual development (puberty) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/21/1363\">",
"         Patient information: Teen sexuality (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Late puberty (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/late-puberty-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11142931\">",
"      <span class=\"h1\">",
"       What is late puberty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Puberty is a term for the changes in the body that happen as a child becomes an adult. Late puberty is when a child starts puberty much later than normal. The body changes in late puberty are the same as those in normal puberty. They just happen when a child is older.",
"     </p>",
"     <p>",
"      Puberty usually starts between ages 9 to 12 in girls and ages 10 to 13 in boys. With late puberty:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A girl hasn&rsquo;t shown any signs of puberty by age 12. Usually, the first sign of puberty in girls is that the breasts grow bigger.",
"       </li>",
"       <li>",
"        A boy hasn&rsquo;t shown any signs of puberty by age 14. Usually, the first sign of puberty in boys is that the testicles get bigger (",
"        <a class=\"graphic graphic_figure graphicRef68075 \" href=\"UTD.htm?21/43/22194\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11142946\">",
"      <span class=\"h1\">",
"       What causes late puberty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Puberty is caused by hormones in the body. The brain makes hormones that start puberty. These hormones travel to the testicles (in boys), and the ovaries (in girls) (",
"      <a class=\"graphic graphic_figure graphicRef68075 \" href=\"UTD.htm?21/43/22194\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 2",
"      </a>",
"      ). The brain hormones signal the testicles to make a hormone called &ldquo;testosterone.&rdquo; They signal the ovaries to make a hormone called &ldquo;estrogen.&rdquo; Estrogen and testosterone cause the changes in the body.",
"     </p>",
"     <p>",
"      Late puberty can happen if this process doesn&rsquo;t happen on time. But it doesn&rsquo;t mean your child has a medical problem. Some children start puberty late because:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        They are growing more slowly than other children. This can be normal.",
"       </li>",
"       <li>",
"        Late puberty runs in their family. If a parent went through puberty late, chances are good that their child will, too. This is especially true for boys.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other children start puberty late because of a medical problem or condition. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An abnormal growth or other problem in the brain, ovaries, or testicles",
"       </li>",
"       <li>",
"        A long-term illness or condition",
"       </li>",
"       <li>",
"        Problems caused by abnormal genes that babies can be born with",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children (especially girls) can also start puberty late if they are too thin, don&rsquo;t eat enough, or exercise much more than normal. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11142961\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your child isn&rsquo;t showing any signs of puberty, the doctor or nurse will want to know why. He or she will talk with you and your child, and do an exam. He or she will also probably do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        X-rays of 1 of your child&rsquo;s hands and wrists &ndash; These X-rays can show how fast your child is growing.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on these results, the doctor might do other tests. These can include more blood tests or a CT scan, ultrasound, or other imaging test of your child&rsquo;s brain or belly. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      The doctor or nurse will also do repeat exams over time to follow your child&rsquo;s growth and development.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11142976\">",
"      <span class=\"h1\">",
"       How is late puberty treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your child&rsquo;s age and the cause of the late puberty.",
"     </p>",
"     <p>",
"      If puberty is late because of a medical problem, the doctor will treat the problem (if it can be treated). Different treatments might include medicines (such as hormones) or surgery. After treatment, your child will most likely start puberty.",
"     </p>",
"     <p>",
"      If your child is normal but growing slowly, or if late puberty runs in his or her family, treatment usually involves &ldquo;watching and waiting&rdquo; for puberty to start on its own.",
"     </p>",
"     <p>",
"      If your child is underweight or exercises too much, the doctor can give you advice about how to help your child get to a healthy weight and have a healthy lifestyle.",
"     </p>",
"     <p>",
"      Some children (mostly boys) who are normal but growing slowly are treated with hormone treatment to help start puberty. Doctors usually recommend this treatment only if late puberty is having a big impact on the child&rsquo;s life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11142991\">",
"      <span class=\"h1\">",
"       What else can I do to help my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can help your child feel good about him or herself. Point out your child&rsquo;s strengths instead of focusing on his or her body. Some children who start puberty late can have a hard time fitting in, because they look younger than other children their age.",
"     </p>",
"     <p>",
"      If your child is teased or treated badly, talk to the doctor or nurse about ways to get help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11143006\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=see_link\">",
"       Patient information: Normal sexual development (puberty) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/21/1363?source=see_link\">",
"       Patient information: Teen sexuality (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=see_link\">",
"       Patient information: Acne (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=see_link\">",
"       Patient information: My child is short (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/31/13810?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16738 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13810=[""].join("\n");
var outline_f13_31_13810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11142931\">",
"      What is late puberty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11142946\">",
"      What causes late puberty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11142961\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11142976\">",
"      How is late puberty treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11142991\">",
"      What else can I do to help my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11143006\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"      Male reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"       Female reproductive anatomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=related_link\">",
"      Patient information: My child is short (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/21/1363?source=related_link\">",
"      Patient information: Teen sexuality (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_31_13811="Scabies hand";
var content_f13_31_13811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, excoriated papules are present on the hand of this patient with scabies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13811=[""].join("\n");
var outline_f13_31_13811=null;
var title_f13_31_13812="Digital myxoid cyst";
var content_f13_31_13812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digital myxoid cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13812=[""].join("\n");
var outline_f13_31_13812=null;
var title_f13_31_13813="Widow bite";
var content_f13_31_13813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Redback spider bite",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The blanched circular patch with a surrounding red perimeter and central punctum is typical for widow spider bites. This lesion was caused by an Australian redback spider (Latrodectus hasselti).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Julian White, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13813=[""].join("\n");
var outline_f13_31_13813=null;
var title_f13_31_13814="Long-term complications of the premature infant";
var content_f13_31_13814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Long-term complications of the premature infant",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/31/13814/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13814/contributors\">",
"     George T Mandy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/31/13814/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13814/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/31/13814/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13814/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/31/13814/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prematurity is defined as a birth that occurs before 37 completed weeks (less than 259 days) of gestation. It is associated with about one-third of all infant deaths in the United States and accounts for approximately 45 percent of children with cerebral palsy, 35 percent of children with vision impairment, and 25 percent of children with cognitive or hearing impairment.",
"   </p>",
"   <p>",
"    Complications of prematurity are the underlying reasons for the higher rate of infant mortality and morbidity in preterm infants compared to full-term infants. The risk of complications increases with increasing immaturity. Thus, infants who are extremely premature, born at or before 25 weeks of gestation, have the highest mortality rate (about 50 percent) and if they survive, are at the greatest risk for long-term morbidity.",
"   </p>",
"   <p>",
"    In preterm survivors, there is a high rate of long-term neurodevelopment impairment and chronic health problems. These chronic medical and neurodevelopmental complications often require additional health care and educational services, which add to the overall economic cost of caring for the premature infant.",
"   </p>",
"   <p>",
"    The long-term complications of prematurity and the long-term health care needs of premature survivors will be reviewed here. The short-term complications of the premature infant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"     \"Short-term complications of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different degrees of prematurity are defined by gestational age (GA) or birth weight.",
"   </p>",
"   <p>",
"    The classification based upon GA is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Late preterm birth &ndash; GA between 34 and less than 37 weeks",
"     </li>",
"     <li>",
"      Very preterm birth &ndash; GA less than 32 weeks",
"     </li>",
"     <li>",
"      Extremely preterm birth &ndash; GA at or below 25 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Premature infants are also classified by birth weight (BW) (",
"    <a class=\"graphic graphic_table graphicRef57685 \" href=\"UTD.htm?1/8/1163\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low birth weight (LBW) &ndash; BW less than 2500 g",
"     </li>",
"     <li>",
"      Very low birth weight (VLBW) &ndash; BW less than 1500 g",
"     </li>",
"     <li>",
"      Extremely low birth weight (ELBW) &ndash; BW less than 1000 g",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Birth weights by percentile for the appropriate GA have been established (",
"    <a class=\"graphic graphic_table graphicRef81379 \" href=\"UTD.htm?10/59/11197\">",
"     table 2",
"    </a>",
"    ). The above definitions are used throughout this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LONG-TERM COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preterm survivors, there is a high rate of recurrent hospitalizations, long-term neurodevelopment impairment and chronic health problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256994956\">",
"    <span class=\"h2\">",
"     Hospitalizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrent hospitalizations increases with decreasing gestational age. This was illustrated in an analysis of data involving 18,818 infants enrolled in the United Kingdom Millennium Cohort Study that showed the risk of three of more hospitalizations between nine months and five years of age was 13.6, 6.9, 4.9, 3.9, and 2.8 for children who were born at a gestational age &lt;32 weeks, 32 to 33 weeks, 34 to 36 weeks, 37 to 38 weeks, and 39 to 41 weeks, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most common causes for rehospitalization were respiratory disorders including respiratory infections, especially respiratory syncytial virus infection, and asthma, and gastrointestinal problems gastroesophageal reflux and gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/1\">",
"     1",
"    </a>",
"    ]. Other chronic medical problems seen in premature survivors include bronchopulmonary dysplasia, increase risk of sudden infant death syndrome, and vision and hearing impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=see_link&amp;anchor=H19#H19\">",
"     \"Care of the neonatal intensive care unit graduate\", section on 'Hospital readmissions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=see_link&amp;anchor=H20#H20\">",
"     \"Care of the neonatal intensive care unit graduate\", section on 'Common medical problems'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurodevelopmental outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature survivors compared to those born full-term are more likely to have the following neurodevelopment disabilities. The risk of these impairments increases with decreasing gestational age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired cognitive skills",
"     </li>",
"     <li>",
"      Motor deficits including mild fine or gross motor delay, and cerebral palsy",
"     </li>",
"     <li>",
"      Sensory impairment including vision and hearing losses",
"     </li>",
"     <li>",
"      Behavioral and psychological problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The long-term neurodevelopmental outcome in premature infants is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link\">",
"     \"Long-term neurodevelopmental outcome of premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic health issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are born premature, particularly those who were extremely low birth weight (ELBW) infants, have higher rates of chronic medical conditions compared with children who were born full term. This was illustrated in a study that compared overall rates of chronic conditions for ELBW survivors and age- and gender-matched controls at eight years of age (75 versus 37 percent) and at 14 years of age (74 versus 47 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/2\">",
"     2",
"    </a>",
"    ]. ELBW survivors were more likely to have asthma, subnormal cognitive function and functional limitation, be enrolled in individual education programs, and require special services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444700181\">",
"    <span class=\"h2\">",
"     Growth impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very premature children are also more likely to exhibit poor growth compared to those born full-term [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. Poor growth of ELBW children persists into school age as demonstrated by a follow-up study of 241 ELBW children who were assessed for growth and blood pressure at a median age of six years and four months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/3\">",
"     3",
"    </a>",
"    ]. Compared to normative growth data from normal children who were born full term, children who were ELBW infants were lighter, shorter, and had a lower body mass index and smaller head circumference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523785159\">",
"    <span class=\"h2\">",
"     Impairment of lung function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who were born prematurely are at risk for impaired lung function that may result in reduced exercise capacity or an increase in respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In particular, survivors of prematurity who had BPD are more likely to have respiratory problems as children and adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=see_link&amp;anchor=H7#H7\">",
"     \"Pulmonary outcomes of bronchopulmonary dysplasia\", section on 'Childhood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect on adult health",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the survival rate of preterm infants improves, the potential impact of prematurity on adult health has become more apparent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin resistance &ndash; Preterm adults appear to be more likely to have insulin resistance and higher blood pressure compared to adults born full-term [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. In one study, adults (18 to 27 years of age) who were born prematurely (birth weights below 1500 g and a mean GA of 29 weeks) compared to full-term controls had higher blood pressure and impaired glucose regulation when evaluated by a standard 75 g oral glucose tolerance test with higher serum glucose and insulin concentrations two hours after glucose administration [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertension and vascular changes &ndash; Adults born premature may have higher blood pressure compared to those born full-term [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. It has been proposed that low birth weight may play a role in the development of essential hypertension in adulthood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"       \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reproduction &ndash; Prematurity has been associated with decrease reproduction in adulthood. This was illustrated in a large population-based study from Norway of over 500,000 individuals born between 1967 and 1976 and followed through 2004 that demonstrated preterm adults had a lower reproductive rate compared to individuals born full-term [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/13\">",
"       13",
"      </a>",
"      ]. The reproductive rate was lowest in the adults with the lowest GA; rates were 25 and 68 percent in women born at 22 to 27 weeks and at term, respectively (adjusted RR 0.33, 95% CI 0.26-0.42), and were 14 and 50 percent in men born at 22 to 27 weeks and at term, respectively (adjusted RR 0.24, 95% CI 0.17-0.32). In addition, preterm women but not men were at increased risk of having preterm offspring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LONG-TERM HEALTH AND EDUCATIONAL NEEDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, premature survivors are at increased risk for chronic medical and neurodevelopmental complications, which often require additional health care and educational services. As the number of survivors of premature birth increase and reach school-age, it is imperative that their health and educational needs are identified and resources are committed to address their needs. This is especially true for the children who were ELBW infants who are at the greatest risk for poor health and neurodevelopmental outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link&amp;anchor=H6#H6\">",
"     \"Long-term neurodevelopmental outcome of premature infants\", section on 'Extremely preterm infant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated in a study that demonstrated ELBW school-aged children compared to full-term children were more likely to have chronic medical conditions and disabilities resulting in increased use of health and educational services [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/14\">",
"     14",
"    </a>",
"    ]. In this study, 219 ELBW children born between 1992 and 1995 (92 percent of the survivors) and full-term controls were evaluated at eight years of age for chronic medical conditions and the consequences of chronic medical conditions by parent questionnaire, neurologic assessment (including hearing, vision, and cognitive function testing), measurement of academic achievement, and motor skills. Children who were ELBW were at increased risk for asthma, cerebral palsy, loss of visual acuity, limited academic skills, and poor motor skills and adaptive function. These chronic conditions led to increased functional limitations (ie, limited physical ability, decrease social skills, sensorineural deficits, and growth, development, or mental delay) in the ELBW group compared to controls (64 versus 20 percent).",
"   </p>",
"   <p>",
"    As a result of the increased risk of chronic medical conditions and functional limitations, the ELBW group had greater compensatory dependence needs (48 versus 23 percent) including medication use, and need for help or equipment for walking, and other daily routine activities (eg, feeding, dressing, and washing). In addition, the ELBW group more frequently utilized services beyond those routinely required by children (65 versus 27 percent). These included acute care visits to health care professionals, and special school arrangements or an individualized education program.",
"   </p>",
"   <p>",
"    Moderately LBW infants (birth weight between 1500 to 2499 g) are also more likely than normal birth weight infants to have special health care needs (eg, use of medical services",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medication), chronic conditions (eg, intellectual disability [mental retardation], cerebral palsy, or asthma), learning disabilities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    attention-deficit or attention deficit hyperactivity disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SOCIETAL COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;If preterm delivery could be avoided, there would be tremendous savings to society worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. This is demonstrated by the following studies in several different developed countries:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sweden &ndash; In a Swedish cohort study based upon 2002 data from the National Board of Health and Welfare and Statistics Sweden registers of 522,310 young adults born between 1973 and 1979, decreasing gestational age was associated with a stepwise increase in disability rates in young adulthood, and a stepwise decrease in net salary and the likelihood of completing a university education [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/17\">",
"       17",
"      </a>",
"      ]. Government economic assistance was provided to 13 percent of individuals born at 24 to 28 weeks gestation and 6 percent born at 29 to 32 weeks gestation. If preterm delivery could have been avoided, the 2002 estimated economic cost savings would have amounted to 65 million euros.",
"     </li>",
"     <li>",
"      Norway &ndash; In a population-based study of all infants who were born alive and without congenital anomalies in Norway between 1967 and 1983, adults born prematurely at a gestational age between 23 and 27 weeks compared to those born full term were more likely to have cerebral palsy (9.1 versus 0.1 percent), be mentally retarded (4.4 versus 0.4 percent), and receive a disability pension (10.6 versus 1.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/18\">",
"       18",
"      </a>",
"      ]. Among adults without medical disabilities, the gestational age at birth was associated with the level of educational achievement, income level, receipt of Social Security benefits, and the ability to have a family but did not correlate with rates of unemployment or criminal activity.",
"     </li>",
"     <li>",
"      United States &ndash; In 2001, the estimated cost of preterm and low birth weight admissions in the United States was 5.8 billion dollars, which represented 47 percent of costs for all infant hospitalizations and 27 percent of all pediatric stays [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/19\">",
"       19",
"      </a>",
"      ]. The annual cost associated with preterm birth in the United States was estimated to be 26 billion dollars [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/20\">",
"       20",
"      </a>",
"      ]. This included the costs of the medical care of the infants, mothers, and expenditures for the long-term care of patients born preterm.",
"     </li>",
"     <li>",
"      England and Wales &ndash; Based upon 2006 estimates of the number of preterm births and the cost of medical care through the first 18 years of life in England and Wales, the total societal cost was estimated to be almost 3 billion pounds (4.6 billion dollars) at 2006 prices [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/21\">",
"       21",
"      </a>",
"      ]. The mean incremental cost per child was about 23,000 pounds ($35,500) and the cost increased with decreasing age with estimated costs for a very preterm child of 62,000 pounds ($96,000) and for an extremely preterm child 95,000 pounds or ($147,000).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, long-term morbidity is reduced when there is perinatal regionalization of care with maternal transport of women at-risk to deliver a very low birth weight (VLBW) infant to a center that delivers a high volume of VLBW infants and provides level 3 neonatal care. This was illustrated in a cohort Finnish study that reported an increased risk of epilepsy and hyperkinetic disorders in VLBW survivors at five years of age who were cared for in a neonatal level 2 care facility compared with a level 3 center [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13814/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, the risk of retinopathy of prematurity and asthma was higher in survivors who had been transferred to a level 2 facility from a level 3 center. These data suggest that efforts to improve the level of neonatal care will improve long-term morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=see_link\">",
"       \"Patient information: When a baby is born premature (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of prematurity are the underlying reasons for the higher rate of infant mortality and morbidity in preterm infants compared to full-term infants. The risk of complications increases with increasing immaturity. Thus, infants who are extremely premature, born at or before 25 weeks of gestation, have the highest mortality rate (about 50 percent) and if they survive, are at the greatest risk for long-term morbidity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In preterm survivors, long-term neurodevelopmental disability is the major cause of morbidity. In addition, chronic medical problems including respiratory abnormalities and poor growth are common in preterm children resulting in frequent hospitalizations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link\">",
"       \"Long-term neurodevelopmental outcome of premature infants\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5\">",
"       'Chronic health issues'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=see_link&amp;anchor=H19#H19\">",
"       \"Care of the neonatal intensive care unit graduate\", section on 'Hospital readmissions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=see_link&amp;anchor=H20#H20\">",
"       \"Care of the neonatal intensive care unit graduate\", section on 'Common medical problems'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prematurity appears to have long-term effects upon adult health. Premature adults compared to those born full-term appear to have increases in insulin resistance and blood pressure, and a decrease in reproductive rate. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Effect on adult health'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because premature children have a high rate of chronic medical conditions including neurodevelopmental disabilities that result functional limitations, they commonly require additional health care and educational services beyond those routinely required by children. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Long-term health and educational needs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If premature birth could be avoided, there would be tremendous savings to society from reduced expenditures from the initial medical costs for care in the neonatal period and additional health and educational costs in childhood, and increased productivity in adulthood. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Societal cost'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/1\">",
"      Boyle EM, Poulsen G, Field DJ, et al. Effects of gestational age at birth on health outcomes at 3 and 5 years of age: population based cohort study. BMJ 2012; 344:e896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/2\">",
"      Hack M, Schluchter M, Andreias L, et al. Change in prevalence of chronic conditions between childhood and adolescence among extremely low-birth-weight children. JAMA 2011; 306:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/3\">",
"      Bracewell MA, Hennessy EM, Wolke D, Marlow N. The EPICure study: growth and blood pressure at 6 years of age following extremely preterm birth. Arch Dis Child Fetal Neonatal Ed 2008; 93:F108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/4\">",
"      Bocca-Tjeertes IF, Kerstjens JM, Reijneveld SA, et al. Growth and predictors of growth restraint in moderately preterm children aged 0 to 4 years. Pediatrics 2011; 128:e1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/5\">",
"      Smith LJ, van Asperen PP, McKay KO, et al. Reduced exercise capacity in children born very preterm. Pediatrics 2008; 122:e287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/6\">",
"      Fawke J, Lum S, Kirkby J, et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med 2010; 182:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/7\">",
"      Kotecha SJ, Watkins WJ, Paranjothy S, et al. Effect of late preterm birth on longitudinal lung spirometry in school age children and adolescents. Thorax 2012; 67:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/8\">",
"      Bolton CE, Stocks J, Hennessy E, et al. The EPICure study: association between hemodynamics and lung function at 11 years after extremely preterm birth. J Pediatr 2012; 161:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/9\">",
"      Hovi P, Andersson S, Eriksson JG, et al. Glucose regulation in young adults with very low birth weight. N Engl J Med 2007; 356:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/10\">",
"      Rotteveel J, van Weissenbruch MM, Twisk JW, Delemarre-Van de Waal HA. Infant and childhood growth patterns, insulin sensitivity, and blood pressure in prematurely born young adults. Pediatrics 2008; 122:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/11\">",
"      Odberg MD, Sommerfelt K, Markestad T, Elgen IB. Growth and somatic health until adulthood of low birthweight children. Arch Dis Child Fetal Neonatal Ed 2010; 95:F201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/12\">",
"      Kerkhof GF, Breukhoven PE, Leunissen RW, et al. Does preterm birth influence cardiovascular risk in early adulthood? J Pediatr 2012; 161:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/13\">",
"      Swamy GK, Ostbye T, Skjaerven R. Association of preterm birth with long-term survival, reproduction, and next-generation preterm birth. JAMA 2008; 299:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/14\">",
"      Hack M, Taylor HG, Drotar D, et al. Chronic conditions, functional limitations, and special health care needs of school-aged children born with extremely low-birth-weight in the 1990s. JAMA 2005; 294:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/15\">",
"      Stein RE, Siegel MJ, Bauman LJ. Are children of moderately low birth weight at increased risk for poor health? A new look at an old question. Pediatrics 2006; 118:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/16\">",
"      Petrou S, Eddama O, Mangham L. A structured review of the recent literature on the economic consequences of preterm birth. Arch Dis Child Fetal Neonatal Ed 2011; 96:F225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/17\">",
"      Lindstr&ouml;m K, Winbladh B, Haglund B, Hjern A. Preterm infants as young adults: a Swedish national cohort study. Pediatrics 2007; 120:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/18\">",
"      Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med 2008; 359:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/19\">",
"      Russell RB, Green NS, Steiner CA, et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics 2007; 120:e1.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Understanding Premature Birth and Assuring Healthy Outcomes. Societal costs of preterm birth. In: Preterm Birth: Causes, Consequences, and Prevention, Behrman RE, Butler AS (Eds), National Academies Press, Washington, DC 2006. p.398.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/21\">",
"      Mangham LJ, Petrou S, Doyle LW, et al. The cost of preterm birth throughout childhood in England and Wales. Pediatrics 2009; 123:e312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13814/abstract/22\">",
"      Rautava L, Eskelinen J, H&auml;kkinen U, et al. 5-year morbidity among very preterm infants in relation to level of hospital care. JAMA Pediatr 2013; 167:40.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5033 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13814=[""].join("\n");
var outline_f13_31_13814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LONG-TERM COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256994956\">",
"      Hospitalizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurodevelopmental outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic health issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444700181\">",
"      Growth impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523785159\">",
"      Impairment of lung function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect on adult health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LONG-TERM HEALTH AND EDUCATIONAL NEEDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SOCIETAL COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/8/1163\" title=\"table 1\">",
"      Definition of prematurity based on birth weights",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/59/11197\" title=\"table 2\">",
"      Birth weight by gestational age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=related_link\">",
"      Care of the neonatal intensive care unit graduate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=related_link\">",
"      Long-term neurodevelopmental outcome of premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=related_link\">",
"      Patient information: When a baby is born premature (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=related_link\">",
"      Pulmonary outcomes of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_31_13815="Ruptured abdominal aortic aneurysm with contrast extravasation";
var content_f13_31_13815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Ruptured abdominal aortic aneurysm with contrast extravasation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A ruptured infrarenal aortic aneurysm is identified with acute extravasation of contrast between the layers of chronic laminated thrombus. Extravasated blood can be seen in the posterior pararenal space (arrow), perirenal space (arrowhead), and in the anterior pararenal space (dashed arrow). The right kidney is displaced posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13815=[""].join("\n");
var outline_f13_31_13815=null;
var title_f13_31_13816="Gestational trophoblastic disease: Pathology";
var content_f13_31_13816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gestational trophoblastic disease: Pathology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/31/13816/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13816/contributors\">",
"     Rebecca N Baergen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/31/13816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13816/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/31/13816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13816/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/31/13816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational trophoblastic disease comprises a heterogeneous group of related lesions arising from abnormal proliferation of trophoblast of the placenta. The pathogenesis of gestational trophoblastic disease is unique, because the maternal lesions arise from fetal, not maternal, tissue.",
"   </p>",
"   <p>",
"    The histopathology of gestational trophoblastic disease is discussed here. The epidemiology, clinical manifestations, diagnosis, and treatment of hydatidiform moles and malignant gestational trophoblastic disease are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23015?source=see_link\">",
"     \"Gestational trophoblastic disease: Management of hydatidiform mole\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gestational trophoblastic disease (GTD) &mdash; Lesions characterized by abnormal proliferation of trophoblast of the placenta. This category is comprised of benign, nonneoplastic lesions including placental site nodule, exaggerated placental site and hydatidiform moles as well as malignant neoplasms.",
"     </li>",
"     <li>",
"      Gestational trophoblastic neoplasia (GTN) &mdash; Gestational neoplasms include: choriocarcinoma, placental site trophoblastic tumor, epithelioid trophoblastic tumor, and invasive moles that do not resolve spontaneously. In the absence of tissue for a definitive histopathological diagnosis, disease diagnosed as a result of persistent elevation of hCG after evacuation of a molar pregnancy is termed GTN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most, but not all, GTD produces the beta subunit of human chorionic gonadotropin (hCG). Chromosomal abnormalities are characteristic of some GTD subtypes; assessment of DNA content enhances the diagnostic accuracy of histological diagnosis (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Genetics'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Types of GTD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are various histologically distinct subtypes of GTD:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Benign nonneoplastic trophoblastic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;These lesions are frequently diagnosed only as an incidental finding on an endometrial curettage or hysterectomy specimen.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exaggerated placental site",
"     </li>",
"     <li>",
"      Placental site nodule",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hydatidiform mole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydatidiform moles result from abnormalities in fertilization. They are essentially benign, but carry an increased risk of persistent or malignant GTN.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete hydatidiform mole",
"     </li>",
"     <li>",
"      Partial hydatidiform mole",
"     </li>",
"     <li>",
"      Invasive mole (chorioadenoma destruens)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Gestational trophoblastic neoplasia (GTN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;True GTN comprises a group of tumors with the potential for local invasion and metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast to other more common malignancies, GTN is curable in 85 to 100 percent of cases, even in the presence of advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Choriocarcinoma",
"     </li>",
"     <li>",
"      Placental site trophoblastic tumor",
"     </li>",
"     <li>",
"      Epithelioid trophoblastic tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molar pregnancies have excess paternal chromosomes. Complete moles develop due to loss of genetic material from the oocyte which is then fertilized by two sperm or one sperm that duplicates its chromosomes. Therefore, complete moles consist of only paternal DNA. Partial moles develop due to fertilization of an oocyte by two sperm resulting in triploidy with a 2:1 paternal to maternal DNA content. GTN may have contributions from both paternal and maternal genomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is known that imprinting has a role in the development of molar pregnancies and GTD. Paternal genes have more control over placental growth while maternal genes have more control over fetal growth. Thus, with excess paternal genes, there is excessive placental or trophoblastic proliferation. There is also a difference between the malignant potential of moles that are heterozygous (arising from two sperm) and homozygous (arising from a single sperm with duplication of DNA). This was illustrated in a study that detected Y chromatin in only 9 percent of hydatidiform moles, but 50 percent of invasive moles, and 74 percent of choriocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have described interesting molecular pathways that might contribute to the development of GTD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/3\">",
"     3",
"    </a>",
"    ]. Somatic point mutations and instability of mitochondrial DNA were found in samples of hydatidiform moles and choriocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/6\">",
"     6",
"    </a>",
"    ]. Amplification and overexpression of various oncogene products, such as c-erbB-2, c-myc, c-fms and mdm-2 have been shown to be associated with a higher proliferation index, more aggressive behavior and development of malignancy in GTD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Epidermal growth factor receptor (EGFR) is highly expressed in choriocarcinoma and complete hydatidiform moles, possibly presenting a therapeutic target [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/9\">",
"     9",
"    </a>",
"    ]. Downregulation of tumor suppressor genes, including p53, p21 and Rb, has also been demonstrated in GTD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Finally, telomerase activity and expression of cell-cell adhesion molecules, metalloproteinases, and tissue inhibitors of metalloproteinases have been suggested to have a role [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BENIGN NONNEOPLASTIC TROPHOBLASTIC LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign trophoblastic lesions are frequently diagnosed only as an incidental finding in a pathology specimen after uterine curettage or hysterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Exaggerated placental site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exaggerated placental site (EPS) is characterized by an extensive infiltration of the endometrium and myometrium by implantation site intermediate (extravillous) trophoblastic cells that occur in clusters or as single cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/12\">",
"     12",
"    </a>",
"    ]. There is no destruction of the normal endometrial glands and stroma, and it occurs in the presence of a current pregnancy, ie, chorionic villi. It likely represents an excessive physiologic process rather than a true lesion; the distinction between a normal placental site and an EPS is often subjective.",
"   </p>",
"   <p>",
"    The EPS can occur in a normal pregnancy or after a first trimester abortion. The associated placenta is usually normal. However, EPS occurs with increased frequency in molar pregnancies and thus can give a clue to diagnosis of these lesions. The trophoblastic cells contain abundant amphophilic to eosinophilic cytoplasm with hyperchromatic, irregularly shaped nuclei, but fail to show mitotic activity. The lack of mitotic activity and association with chorionic villi is an important clue in diagnosis, particularly between EPS and placental site trophoblastic tumor (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Gestational trophoblastic neoplasia (GTN)'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The protein expression pattern of the trophoblastic cells in the EPS by immunohistochemistry is comparable to the implantation site intermediate (extravillous) trophoblastic cells found in the normal placental site. Thus they show strong expression for hPL and Mel-CAM (CD146) with focal positivity for PLAP. This is the same profile as seen in placental site trophoblastic tumors (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Gestational trophoblastic neoplasia (GTN)'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Placental site nodule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental site nodules (PSN) are found in uterine curettages and cervical or hysterectomy specimens in reproductive age patients. In one series, 40 percent of PSNs were located in the endocervix, 56 percent were in the endometrium, and 4 percent were found in the fallopian tube [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/13\">",
"     13",
"    </a>",
"    ]. The intermediate trophoblastic cells of PSNs are likely derived from the migratory intermediate (extravillous) trophoblasts of the placenta similar to the trophoblast in the chorion laeve and chorionic plate rather than the invasive intermediate trophoblast of the implantation site. They represent the nonneoplastic counterpart of epithelioid trophoblastic tumors (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Gestational trophoblastic neoplasia (GTN)'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In about one half of cases, PSNs are discovered as an incidental finding in curettage or hysterectomy specimens. When grossly identifiable, they are characterized by a yellow or tan surface and range from 1 to 14 mm (average 2.1 mm) in size. They are occasionally found as multiple nodules or plaques. Histologically, the nodules are well circumscribed and surrounded by a thin rim of chronic inflammatory cells. Abundant hyalinized or fibrinoid extracellular matrix separates trophoblastic cells which are small and monomorphic compared with implantation site trophoblast. They tend to have vacuolated cytoplasm and a somewhat degenerated appearance. Mitotic figures are rare and usually absent. PSNs express the intermediate trophoblastic markers of migratory trophoblast, and therefore show strong diffuse staining for PLAP, but only focal staining for hPL and Mel-CAM (CD146) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HYDATIFORM MOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hydatidiform mole is the most common form of GTD, representing 80 percent of cases. Moles may be complete, partial, or invasive. Complete and partial hydatidiform moles are differentiated by their karyotype, gross morphology, histologic appearance, and clinical features; invasive moles act in an aggressive manner and are often treated similarly to choriocarcinomas.",
"   </p>",
"   <p>",
"    The development of GTN is significantly increased after a complete mole, but only slightly increased after a partial mole. A review of 3000 partial moles (triploid and nontriploid) found that only 15 (0.5 percent) required chemotherapy for GTN, and only rarely, if ever, develop into choriocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/14\">",
"     14",
"    </a>",
"    ]. When strict criteria are used for the diagnosis of partial moles including the presence of triploidy, no cases of choriocarcinoma have been reported to develop (0 out of 196 cases of triploid partial mole) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23015?source=see_link\">",
"     \"Gestational trophoblastic disease: Management of hydatidiform mole\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Genetics of molar pregnancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complete mole genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete mole most commonly has a 46,XX karyotype, with all chromosomes of paternal origin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/16\">",
"     16",
"    </a>",
"    ]. This results from fertilization of an \"empty\" egg (ie, absent or inactivated maternal chromosomes) by a haploid sperm that then duplicates (46,YY moles do not occur because this karyotype is lethal). A small number (3 to 13 percent) of complete moles have a 46,XY chromosome complement; this is thought to occur when an empty ovum is fertilized by two sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/16\">",
"     16",
"    </a>",
"    ]. A few complete moles have a 46,XX karyotype but develop from fertilization of an empty ovum by two sperm. Because the nucleus is entirely paternal in origin, a complete mole is actually a paternal allograft in the mother. Aneuploidy can also occur and rarely tetraploid complete moles have been described.",
"   </p>",
"   <p>",
"    Rarely, complete moles are biparental and are associated with an autosomal recessive condition predisposing to molar pregnancy. These patients often have recurrent hydatiform moles. This defect is likely due to dysregulation of genomic imprinting, in some cases related to a mutation at the 1.1 MB region on chromosome 19q13.4 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. As an example, women with biparental complete mole have significant underexpression of p57(KIP2), which is the product of CDKN1C (an imprinted, maternally expressed gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with women with androgenic complete moles, women with biparental complete moles have a very high risk of recurrence, and also an increased risk of persistent trophoblastic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/17\">",
"     17",
"    </a>",
"    ]. In one series of 152 pregnancies among 37 women with familial recurrent mole, complete mole and partial moles occurred in 74 and 4 percent of pregnancies, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/19\">",
"     19",
"    </a>",
"    ]. A normal pregnancy developed in only 5 percent, the remainder were described as spontaneous abortions (17 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Partial mole genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial moles are pathologically and karyotypically distinct from complete moles. They are usually (about 90 percent) triploid (69,XXX, 69,XXY, rarely 69,XYY) due to the fertilization of an ovum (one set of haploid maternal chromosomes) by two sperm (two sets of haploid paternal chromosomes). Flow cytometry studies have revealed a variety of other karyotypes in the remaining 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/20\">",
"     20",
"    </a>",
"    ], although the true existence of nontriploid partial mole has been challenged [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/21\">",
"     21",
"    </a>",
"    ]. The fetal or embryonic tissue that is present with a partial mole will most commonly have a triploid karyotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydatidiform moles are characterized by a marked proliferation of villous trophoblast associated with hydropic swelling of the chorionic villi. A major difference between the two types of molar pregnancy is that complete moles typically do not contain",
"    <span class=\"nowrap\">",
"     fetal/embryonic",
"    </span>",
"    tissue and partial moles do, although",
"    <span class=\"nowrap\">",
"     fetal/embryonic",
"    </span>",
"    tissue may be present in complete moles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/22\">",
"     22",
"    </a>",
"    ]. The genetics of complete and partial mole also differ (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Genetics'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Complete mole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chorionic villi of a complete mole are diffusely hydropic and surrounded by hyperplastic, often atypical, trophoblast (",
"    <a class=\"graphic graphic_table graphicRef75598 \" href=\"UTD.htm?13/63/14332\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65964 \" href=\"UTD.htm?25/60/26569\">",
"     picture 1",
"    </a>",
"    ). Fetal tissue is not typically present. A twin pregnancy may be complicated by GTD, with a combination of a normal conceptus and a mole (complete or partial) and viable fetus or two moles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genetic differences between complete and partial moles allow for differentiation between these two types of GTD by immunohistochemistry. As noted in a preceding section, the p57(kip2) protein is the product of a paternally imprinted, maternally expressed gene. Immunohistochemical staining for p57 is therefore absent in complete moles (paternal, but no maternal genome) and present in partial moles or non-molar hydropic abortuses (both paternal and maternal genetic material) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/23\">",
"     23",
"    </a>",
"    ]. p57 is strongly imprinted in villous cytotrophoblasts, this imprinting does not occur in extravillous trophoblasts (intermediate trophoblasts). Therefore, extravillous trophoblasts will express p57 in both partial and complete moles, and extravillous trophoblasts and decidual tissue serve as good internal controls for this immunostain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Early complete mole",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the advent of ultrasonography at earlier gestational ages, molar pregnancies are being detected increasingly early, often as early as eight or nine weeks of gestation. The histologic features so characteristic of traditional complete moles, large hydropic villi and extensive trophoblast hyperplasia, are not typically seen at these early stages of development. Here, the differential diagnosis is usually between a hydropic abortus and an early complete mole.",
"   </p>",
"   <p>",
"    There are, however, distinctive histologic features seen in these \"early complete moles\" (often defined as a complete mole identified before 10 weeks gestational age). These include a cellular, myxoid-like villous stroma; markedly irregular villous contours (referred to as \"toes and knuckles\"); karyorrhectic debris visible in the villous stroma; and atypical trophoblasts (both villous and extravillous). Trophoblastic proliferation is not as marked as in more mature moles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/24\">",
"     24",
"    </a>",
"    ]. In difficult cases, the use of p57 immunohistochemistry can be very helpful in identifying early complete moles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/23,25\">",
"     23,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Partial mole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to complete mole, a partial mole often contains normal appearing chorionic villi and fetal tissue admixed with hydropic villi. The hydropic changes are focal and less prominent with less trophoblastic hyperplasia and atypia (",
"    <a class=\"graphic graphic_picture graphicRef53787 \" href=\"UTD.htm?43/14/44264\">",
"     picture 2",
"    </a>",
"    ). Marked scalloping of chorionic villi and trophoblastic stromal inclusions are also common. Differentiation of a partial mole from a hydropic abortus may be problematic. However, hydropic abortuses usually have a spectrum of villous sizes versus the two populations of villi in partial moles. Also, abortuses will have attenuated trophoblast over the surface of the hydropic villi while partial moles show at least modest trophoblastic proliferation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Invasive mole",
"    </span>",
"    &nbsp;&mdash;&nbsp;An invasive mole is a hydatidiform mole characterized by the presence of enlarged hydropic villi invading into the myometrium, into vascular spaces, or into extrauterine sites. The abnormal villi penetrate deeply into the myometrium. These lesions may be differentiated from choriocarcinoma in that they contain hydropic villi along with the marked trophoblastic proliferation. Both invasive moles and choriocarcinoma may show invasion of the uterine vasculature and the production of secondary metastatic lesions, particularly involving the vagina and lungs. Invasive moles do not often resolve spontaneously. Histologic confirmation of the clinical diagnosis is usually not pursued. Invasion can be difficult to diagnose by curettage, as myometrium is often not present. Thus, it is usually only diagnosed histologically if a hysterectomy has been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     GESTATIONAL TROPHOBLASTIC NEOPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The group of true gestational trophoblastic neoplasia includes choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). As noted in the preceding section, invasive mole that does not resolve spontaneously is also GTN. Each of these neoplasms can follow a normal pregnancy or a molar pregnancy. Choriocarcinoma follows a mole in 50 percent of cases, while PSTT and ETT follow a mole in only 8 percent of cases.",
"   </p>",
"   <p>",
"    Data from protein expression studies and immunohistochemical profiles have shown the presence of a common trophoblast stem cell that subsequently develops along one of three possible lines of differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Choriocarcinoma is thought to be the most \"undifferentiated\" trophoblastic tumor compared to PSTT and ETT as the latter two tumors show phenotypic characteristics of extravillous intermediate trophoblast cells either in an implantation site (PSTT) or the migratory intermediate trophoblast (ETT).",
"   </p>",
"   <p>",
"    However, more convincing data have shown that the common trophoblastic stem cell develops along",
"    <strong>",
"     two",
"    </strong>",
"    lines of trophoblastic differentiation: villous and extravillous [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/28\">",
"     28",
"    </a>",
"    ]. Molar pregnancies and choriocarcinoma are derived from villous trophoblast and PSTT and ETT are derived from extravillous trophoblast. Further differentiation along the extravillous (intermediate) trophoblast line produces invasive trophoblast which are involved in remodeling and invasive of the implantation site from which PSTT is derived and the migratory trophoblast that are present in other parts of the placenta like the chorionic plate, fetal membranes, cell islands and so on, from which ETT is derived.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     GTN following molar pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the evacuation of a molar pregnancy, trophoblastic tissue persists in about 20 percent of patients overall, but in a greater proportion of high risk patients. Higher risk is associated with older age, longer interval from previous pregnancy and higher beta-hCG levels. Surveillance is essential after the evacuation of a molar pregnancy to exclude the presence of persistent disease. The diagnosis is usually based upon the finding of stable or serially rising serum beta-hCG concentrations rather than by examination of tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23015?source=see_link\">",
"     \"Gestational trophoblastic disease: Management of hydatidiform mole\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Molar pregnancy with a persistent hCG elevation is considered to be persistent or recurrent GTN. Often there is no histolopathologic confirmation and patients are treated empirically. Histologically, 75 percent of cases of stable or serially rising serum hCG concentrations after a molar pregnancy represent invasive moles and 25 percent are choriocarcinomas. PSTTs do not usually occur in this context.",
"   </p>",
"   <p>",
"    The risk of choriocarcinoma is increased after a complete mole and has only rarely been reported after a partial mole [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23015?source=see_link\">",
"     \"Gestational trophoblastic disease: Management of hydatidiform mole\"",
"    </a>",
"    .) Therefore, a rise in serum hCG after a molar pregnancy signals the presence of persistent or recurrent gestational trophoblastic disease, which may be a recurrent mole, invasive mole, or choriocarcinoma. In contrast, persistent elevation of serum hCG following any nonmolar pregnancy, eg, miscarriage, ectopic, or",
"    <span class=\"nowrap\">",
"     preterm/term",
"    </span>",
"    pregnancy, may be due to development of choriocarcinoma or PSTT (rare) rather than invasive mole [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Types of GTN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Choriocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choriocarcinoma is a highly malignant epithelial tumor. It can arise from any type of trophoblastic tissue (molar pregnancy, abortion, ectopic,",
"    <span class=\"nowrap\">",
"     preterm/term",
"    </span>",
"    intrauterine pregnancy) but, as noted in the preceding section, occurs only rarely, if ever, after a partial mole [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/14,29\">",
"     14,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, choriocarcinoma consists of sheets of anaplastic cytotrophoblasts and syncytiotrophoblasts without chorionic villi. While some trophoblasts, which are intermediate in appearance, may also be seen, the biphasic pattern of obviously malignant appearing mononuclear (cytotrophoblasts) and multinuclear cells (syncytiotrophoblasts) is essentially pathognomonic of choriocarcinoma (",
"    <a class=\"graphic graphic_picture graphicRef68572 \" href=\"UTD.htm?16/15/16633\">",
"     picture 3",
"    </a>",
"    ). Extensive necrosis, hemorrhage, and vascular invasion are common.",
"   </p>",
"   <p>",
"    Choriocarcinoma following a normal gestation is often comprised of biparental chromosomes identical to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/30\">",
"     30",
"    </a>",
"    ]. However, this is not always the case as some choriocarcinomas do not have the DNA complement of the previous pregnancy, but rather the pregnancy preceding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/31\">",
"     31",
"    </a>",
"    ]. Postmolar choriocarcinoma is often comprised exclusively of paternal DNA; most choriocarcinomas that follow molar pregnancies are aneuploid [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most lesions begin in the uterus, although ectopic pregnancies provide extrauterine sites of origin. When choriocarcinoma metastasizes, the most common sites are lung, brain, liver, pelvis, vagina, spleen, intestine, and kidney.",
"   </p>",
"   <p>",
"    Sometimes, when curettage is performed for an early pregnancy loss, immature gestational tissue without villi adjacent to regions of atypia may be encountered. Histopathologic diagnosis of choriocarcinoma in the setting of an early pregnancy is often problematic. Although the presumptive diagnosis is a missed abortion, choriocarcinoma may have to be excluded by following quantitative serum hCG concentrations and performing a chest radiograph.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Placental site trophoblastic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSTT, initially described in 1981, is a rare, potentially malignant neoplasm originating from extravillous (intermediate) trophoblast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/32\">",
"     32",
"    </a>",
"    ]. Approximately 300 cases of PSTT had been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. They can occur months to years after a pregnancy. PSTTs most commonly develop after a term gestation, but also occur after a molar pregnancy in about 8 percent of cases; a PSTT can develop after any type of pregnancy. The majority of PSTTs, approximately 70 percent, act in a benign manner while the remaining 30 percent can develop metastasis and even result in death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On histological examination, PSTT generally presents as a proliferation of extravillous or intermediate trophoblast in the myometrium or endomyometrium (",
"    <a class=\"graphic graphic_picture graphicRef52529 \" href=\"UTD.htm?27/48/28424\">",
"     picture 4",
"    </a>",
"    ). Chorionic villi are rarely found and the typical dimorphic pattern of choriocarcinoma is absent. Instead, there is a characteristic pattern consisting of a relatively monomorphic population of predominantly mononuclear trophoblastic cells infiltrating the myometrium and splitting apart the muscle fibers. Scattered multinucleated trophoblasts are also present as are multinucleated syncytiotrophoblastic-like cells. Nuclear atypia is quite variable as is the cytoplasm which is most often amphophilic but can also be eosinophilic or clear. Spindling of tumor cells may be present. In addition, there is usually abundant fibrinoid material and prominent vascular invasion. A variable amount of inflammation and necrosis is identified but the marked hemorrhage and necrosis typical of choriocarcinoma is not present.",
"   </p>",
"   <p>",
"    Immunohistochemical staining for human placental lactogen (hPL), CD146 (MEL-CAM), and placental alkaline phosphatase (PLAP) are additional diagnostic tests for PSTT that have a specificity of approximately 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/13,35\">",
"     13,35",
"    </a>",
"    ]. Mel-CAM and hPL are usually strongly positive, while PLAP is focally positive consistent with origin from implantation site trophoblast. In addition, high proliferative activity (as assessed by Ki-67 staining) and positive staining for alpha-inhibin and cytokeratin",
"    <span class=\"nowrap\">",
"     8/18",
"    </span>",
"    and negative smooth muscle markers confirm the diagnosis of PSTT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/13\">",
"     13",
"    </a>",
"    ]. Most PSTTs are diploid, although a report of a tumor with triploid cells has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the majority of PSTTs are considered benign, there is no specific clinical or pathologic feature on which one may rely to determine malignant behavior. However, there are a number of adverse prognostic factors which, when present, confer a greater likelihood of malignant behavior. These include advanced stage, older age, longer interval from previous pregnancy, previous term pregnancy, higher serum hCG level, higher mitotic rate, coagulative tumor necrosis and clear cytoplasm. When a PSTT is malignant, it is fairly resistant to chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Epithelioid trophoblastic tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;ETT is a rare form of trophoblastic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/37\">",
"     37",
"    </a>",
"    ]. As of 2008, only 52 cases had been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/38\">",
"     38",
"    </a>",
"    ]. ETTs are clinically, pathologically and prognostically similar to PSTTs. ETT primarily occurs in reproductive-age women up to 18 years following a prior gestation. The majority of ETT occurs after a full-term pregnancy, but about one third arise following a spontaneous abortion or hydatidiform mole [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal bleeding is the presenting symptom in two-thirds of patients; about one-third of patients present with metastatic disease. Serum hCG levels are elevated, but usually do not exceed 2500 milli-international",
"    <span class=\"nowrap\">",
"     units/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Gross inspection of ETT shows a solid to cystic, fleshy, and well-defined mass in the uterine wall, lower uterine segment, or endocervix. Histologically ETT is nodular, with proliferation of smaller, more monomorphic trophoblastic cells in comparison to PSTT. The cells display eosinophilic to clear cytoplasm forming numerous cell nests with surrounding necrosis. The borders of nodular growth are usually well circumscribed, but focal invasion into the surrounding tissue is frequently found. The predominant cell type is the migratory type of extravillous or intermediate trophoblast, but occasional syncytiotrophoblast-type cells may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/39\">",
"     39",
"    </a>",
"    ]. Mitotic rate is variable, from 0 to 9 per 10 high-power fields.",
"   </p>",
"   <p>",
"    Behavior and prognosis is similar to that of PSTT. A minority of ETTs act in a malignant manner and treatment is usually problematic in those cases.",
"   </p>",
"   <p>",
"    Molecular markers expressed on ETT by immunohistochemistry include pancytokeratin, epithelial membrane antigen, cytokeratin 18, inhibin-a, hCG, human placental lactogen, placental alkaline phosphate, and Mel-CAM (CD146). P63 is expressed in ETT, placental site nodule, and choriocarcinoma, but not in PSTT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13816/abstract/40\">",
"     40",
"    </a>",
"    ]. Placental alkaline phosphatase staining is usually strong while hPL, inhibin and Mel-CAM staining is usually more weak and focal.",
"   </p>",
"   <p>",
"    Epithelioid trophoblastic tumor can be confused with squamous cell carcinoma because of its frequent involvement of the lower uterine segment or endocervix, its epithelioid histologic appearance, and expression of p63 and cytokeratins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gestational trophoblastic disease (GTD) is characterized by abnormal trophoblastic proliferation. In GTD, the lesion arises from fetal, not maternal, tissue. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GTD may be nonneoplastic or neoplastic. Nonneoplastic GTD includes exaggerated placental site, placental site nodule, and complete or partial hydatidiform mole. Gestational neoplasia includes invasive mole, choriocarcinoma, placental site trophoblastic tumor (PSTT), or epithelioid trophoblastic tumor (ETT). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Gestational trophoblastic neoplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hydatidiform moles, choriocarcinomas and the majority of PSTTs and ETTs are identified by a marker, the beta subunit of human chorionic gonadotropin or by the marker for human placental lactogen. Moles have characteristic chromosomal abnormalities. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A complete mole usually has a 46,XX karyotype (rarely, a 46 XY karyotype), but both sets of chromosomes are of paternal origin. Partial moles are typically triploid due to the fertilization of an ovum by two sperm. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the evacuation of a molar pregnancy, trophoblastic tissue persists in about 20 percent of patients. Malignant GTD usually occurs after a complete mole, rather than a partial mole and consists of an invasive mole in 75 percent of cases and choriocarcinoma in 25 percent; other types of GTN are rare. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Gestational trophoblastic neoplasia (GTN)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent elevation of serum hCG following any nonmolar pregnancy, eg, miscarriage, ectopic, or",
"      <span class=\"nowrap\">",
"       preterm/term",
"      </span>",
"      pregnancy, is more commonly due to choriocarcinoma rather than placental site trophoblastic tumor or invasive mole. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Gestational trophoblastic neoplasia (GTN)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/1\">",
"      van de Kaa CA, Schijf CP, de Wilde PC, et al. The role of deoxyribonucleic acid image cytometric and interphase cytogenetic analyses in the differential diagnosis, prognosis, and clinical follow-up of hydatidiform moles. A report from the Central Molar Registration in The Netherlands. Am J Obstet Gynecol 1997; 177:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/2\">",
"      Cheung AN, Khoo US, Lai CY, et al. Metastatic trophoblastic disease after an initial diagnosis of partial hydatidiform mole: genotyping and chromosome in situ hybridization analysis. Cancer 2004; 100:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/3\">",
"      Shih IeM. Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets. Lancet Oncol 2007; 8:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/4\">",
"      El-Helw LM, Hancock BW. Treatment of metastatic gestational trophoblastic neoplasia. Lancet Oncol 2007; 8:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/5\">",
"      Davis JR, Surwit EA, Garay JP, Fortier KJ. Sex assignment in gestational trophoblastic neoplasia. Am J Obstet Gynecol 1984; 148:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/6\">",
"      Chiu PM, Liu VW, Ngan HY, et al. Detection of mitochondrial DNA mutations in gestational trophoblastic disease. Hum Mutat 2003; 22:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/7\">",
"      Li HW, Tsao SW, Cheung AN. Current understandings of the molecular genetics of gestational trophoblastic diseases. Placenta 2002; 23:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/8\">",
"      Fulop V, Mok SC, Genest DR, et al. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 1998; 43:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/9\">",
"      Tuncer ZS, Vegh GL, Fulop V, et al. Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol Oncol 2000; 77:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/10\">",
"      Fulop V, Mok SC, Genest DR, et al. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 1998; 43:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/11\">",
"      Shih IeM, Kurman RJ. Molecular basis of gestational trophoblastic diseases. Curr Mol Med 2002; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/12\">",
"      Shih IM, Seidman JD, Kurman RJ. Placental site nodule and characterization of distinctive types of intermediate trophoblast. Hum Pathol 1999; 30:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/13\">",
"      Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol 2001; 20:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/14\">",
"      Seckl MJ, Fisher RA, Salerno G, et al. Choriocarcinoma and partial hydatidiform moles. Lancet 2000; 356:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/15\">",
"      Niemann I, Petersen LK, Hansen ES, Sunde L. Predictors of low risk of persistent trophoblastic disease in molar pregnancies. Obstet Gynecol 2006; 107:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/16\">",
"      Jacobs PA, Wilson CM, Sprenkle JA, et al. Mechanism of origin of complete hydatidiform moles. Nature 1980; 286:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/17\">",
"      Fisher RA, Hodges MD. Genomic imprinting in gestational trophoblastic disease--a review. Placenta 2003; 24 Suppl A:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/18\">",
"      Fisher RA, Hodges MD, Rees HC, et al. The maternally transcribed gene p57(KIP2) (CDNK1C) is abnormally expressed in both androgenetic and biparental complete hydatidiform moles. Hum Mol Genet 2002; 11:3267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/19\">",
"      Fisher RA, Hodges MD, Newlands ES. Familial recurrent hydatidiform mole: a review. J Reprod Med 2004; 49:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/20\">",
"      Lage JM, Mark SD, Roberts DJ, et al. A flow cytometric study of 137 fresh hydropic placentas: correlation between types of hydatidiform moles and nuclear DNA ploidy. Obstet Gynecol 1992; 79:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/21\">",
"      Genest DR, Ruiz RE, Weremowicz S, et al. Do nontriploid partial hydatidiform moles exist? A histologic and flow cytometric reevaluation of nontriploid specimens. J Reprod Med 2002; 47:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/22\">",
"      Baergen RN, Kelly T, McGinniss MJ, et al. Complete hydatidiform mole with a coexistent embryo. Hum Pathol 1996; 27:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/23\">",
"      Castrillon DH, Sun D, Weremowicz S, et al. Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2. Am J Surg Pathol 2001; 25:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/24\">",
"      Keep D, Zaragoza MV, Hassold T, Redline RW. Very early complete hydatidiform mole. Hum Pathol 1996; 27:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/25\">",
"      Lipata F, Parkash V, Talmor M, et al. Precise DNA genotyping diagnosis of hydatidiform mole. Obstet Gynecol 2010; 115:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/26\">",
"      Lee Y, Kim KR, McKeon F, et al. A unifying concept of trophoblastic differentiation and malignancy defined by biomarker expression. Hum Pathol 2007; 38:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/27\">",
"      Mao TL, Kurman RJ, Huang CC, et al. Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. Am J Surg Pathol 2007; 31:1726.",
"     </a>",
"    </li>",
"    <li>",
"     Benirschke K, Kaufmann P, Baergen RN. Pathology of the Human Placenta, Springer, New York 2006. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/29\">",
"      Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med 1996; 335:1740.",
"     </a>",
"    </li>",
"    <li>",
"     Lage JM. The placenta. In: Pathology in obstetrics and gynecology, 4th, Gompel C, Silverberg SG (Eds), Lippincott, Philadelphia 1994. p.448.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/31\">",
"      Fisher RA, Newlands ES, Jeffreys AJ, et al. Gestational and nongestational trophoblastic tumors distinguished by DNA analysis. Cancer 1992; 69:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/32\">",
"      Scully RE, Young RH. Trophoblastic pseudotumor: a reappraisal. Am J Surg Pathol 1981; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/33\">",
"      Hoekstra AV, Keh P, Lurain JR. Placental site trophoblastic tumor: a review of 7 cases and their implications for prognosis and treatment. J Reprod Med 2004; 49:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/34\">",
"      Baergen RN, Rutgers JL, Young RH, et al. Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2006; 100:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/35\">",
"      Vardar MA, Altintas A. Placental-site trophoblastic tumor. Principles of diagnosis, clinical behaviour and treatment. Eur J Gynaecol Oncol 1995; 16:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/36\">",
"      Kashimura M, Kashimura Y, Oikawa K, et al. Placental site trophoblastic tumor: immunohistochemical and nuclear DNA study. Gynecol Oncol 1990; 38:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/37\">",
"      Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol 1998; 22:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/38\">",
"      Palmer JE, Macdonald M, Wells M, et al. Epithelioid trophoblastic tumor: a review of the literature. J Reprod Med 2008; 53:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/39\">",
"      Allison KH, Love JE, Garcia RL. Epithelioid trophoblastic tumor: review of a rare neoplasm of the chorionic-type intermediate trophoblast. Arch Pathol Lab Med 2006; 130:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13816/abstract/40\">",
"      Shih IM, Kurman RJ. p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am J Surg Pathol 2004; 28:1177.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3230 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13816=[""].join("\n");
var outline_f13_31_13816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Types of GTD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Benign nonneoplastic trophoblastic lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hydatidiform mole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Gestational trophoblastic neoplasia (GTN)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BENIGN NONNEOPLASTIC TROPHOBLASTIC LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Exaggerated placental site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Placental site nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HYDATIFORM MOLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Genetics of molar pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complete mole genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Partial mole genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Complete mole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Early complete mole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Partial mole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Invasive mole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GESTATIONAL TROPHOBLASTIC NEOPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      GTN following molar pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Types of GTN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Choriocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Placental site trophoblastic tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Epithelioid trophoblastic tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3230|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/60/26569\" title=\"picture 1\">",
"      Complete mole path histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/14/44264\" title=\"picture 2\">",
"      Partial mole histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/15/16633\" title=\"picture 3\">",
"      Choriocarcinoma histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/48/28424\" title=\"picture 4\">",
"      Placental site troph tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3230|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/63/14332\" title=\"table 1\">",
"      Complete versus partial mole",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23015?source=related_link\">",
"      Gestational trophoblastic disease: Management of hydatidiform mole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=related_link\">",
"      Gestational trophoblastic neoplasia: Staging and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_31_13817="Clozapine: Pediatric drug information";
var content_f13_31_13817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clozapine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"    see \"Clozapine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/41/8854?source=see_link\">",
"    see \"Clozapine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clozaril&reg;;",
"     </li>",
"     <li>",
"      FazaClo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clozapine&reg;;",
"     </li>",
"     <li>",
"      Clozaril&reg;;",
"     </li>",
"     <li>",
"      Gen-Clozapine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1006801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Atypical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1006835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"      see \"Clozapine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Treatment of refractory childhood-onset schizophrenia or schizoaffective disorder:",
"     </b>",
"     Limited data available: Oral: Initial: 12.5 mg once or twice daily; increase daily dose as tolerated every 3-5 days (usually by 25 mg increments) to a target dose of 125-475 mg/day in divided doses (based on patient&rsquo;s age, size, and tolerability). Mean dose in most pediatric studies: 175-200 mg/day (Findling, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Refractory schizophrenia or schizoaffective disorder:",
"     </b>",
"     Oral: Initial: 12.5 mg once or twice daily; increase as tolerated, in increments of 25-50 mg/day to a target dose of 300-450 mg/day after 2-4  weeks; may increase further if needed, but no more than once or twice weekly, in increments &le;100 mg/day; some patients may require doses as high as 600-900 mg/day in divided doses. Do not exceed 900 mg/day. In some efficacy studies, total daily dosage was administered in three divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Due to significant adverse effects, patients who fail to adequately respond clinically, should not be normally continued on therapy for an extended period of time; responding patients should be maintained on the lowest effective dose; patients should be periodically assessed to determine if maintenance treatment is still required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reduction of the risk of suicidal behavior in schizophrenia or schizoaffective disorder:",
"     </b>",
"     Oral: Initial: 12.5 mg once or twice daily; increased, as tolerated, in increments of 25-50 mg/day to a target dose of 300-450 mg/day after 2-4-weeks; may increase further if needed, but no more than once or twice weekly, in increments &le;100 mg/day; mean effective dose is ~300 mg/day (range: 12.5-900 mg).",
"     <b>",
"      Note:",
"     </b>",
"     A treatment course of at least 2 years is recommended to maintain the decreased risk for suicidal behavior; patients should be reassessed after 2 years for risk of suicidal behavior and periodically thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Termination of therapy:",
"     </i>",
"     If dosing is interrupted for &ge;48 hours, therapy must be reinitiated at 12.5-25 mg/day; if tolerated, the dose may be increased more rapidly than with initial titration, unless cardiopulmonary arrest occurred during initial titration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In the event of planned termination of clozapine, gradual reduction in dose over a 1- to 2-week period is recommended. If conditions warrant abrupt discontinuation (eg, leukopenia, eosinophilia), monitor patient for psychosis and cholinergic rebound (headache, nausea, vomiting, diarrhea).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for toxicity:",
"     </b>",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eosinophilia: Interrupt therapy for eosinophil count &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; may resume therapy when eosinophil count &lt;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate leukopenia or granulocytopenia (WBC 2000-3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or ANC 1000-1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Discontinue therapy; may rechallenge patient when WBC is &gt;3500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and ANC is &gt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Patient is at greater risk for developing agranulocytosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe leukopenia or granulocytopenia (WBC &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Discontinue therapy and do not rechallenge patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer's labeling (has not been studied); use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer's labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clozaril&reg;: 25 mg, 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 12.5 mg, 25 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FazaClo&reg;: 12.5 mg [contains phenylalanine 0.87 mg/tablet; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FazaClo&reg;: 25 mg [contains phenylalanine 1.74 mg/tablet; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FazaClo&reg;: 100 mg [contains phenylalanine 6.96 mg/tablet; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FazaClo&reg;: 150 mg [contains phenylalanine 10.44 mg/tablet; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FazaClo&reg;: 200 mg [contains phenylalanine 13.92 mg/tablet; mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16156266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Versacloz&trade; oral suspension: FDA approved February 2013; anticipated availability currently unknown.  Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11218426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      U.S.:",
"     </b>",
"     Clozaril&reg; is deemed to have a REMS program (approval pending from FDA). As a requirement of the REMS program, access to this medication is restricted.  Patient-specific registration is required to dispense clozapine. Information specific to each monitoring program is available from the individual manufacturers. If a patient is switched from one brand/manufacturer of clozapine to another, the patient must be entered into a new registry (must be completed by the prescriber and delivered to the dispensing pharmacy). Healthcare providers, including pharmacists dispensing clozapine, should verify the patient's hematological status and qualification to receive clozapine with all existing registries. The manufacturer of Clozaril&reg; requests that healthcare providers submit all WBC/ANC values following discontinuation of therapy to the Clozaril National Registry for all nonrechallengable patients until WBC is  &ge;3500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and ANC is  &ge;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Canada:",
"     </b>",
"     Currently, there are multiple manufacturers that distribute clozapine and each manufacturer has its own registry and distribution system. Patients must be registered in a database that includes their location, prescribing physician, testing laboratory, and dispensing pharmacist before using clozapine. Information specific to each monitoring program is available from the individual manufacturers.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1006841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally-disintegrating tablet: Should be removed from foil blister by peeling apart (do not push tablet through the foil). Remove immediately prior to use. Place tablet in mouth and allow to dissolve; swallow with saliva (no water is needed to take the dose). If dosing requires splitting tablet, throw unused portion away.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1006824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Clozaril&reg;: Store at temperatures &le;30&deg;C (86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FazaClo&reg;: Store at controlled room temperature at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from moisture; do not remove from package until ready to use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dispensed in &ldquo;clozapine patient system&rdquo; packaging.",
"     <b>",
"      Note:",
"     </b>",
"     Drug is usually dispensed in a 1-week supply, unless patient is eligible for WBC and ANC testing at greater intervals (eg, every 2 or 4 weeks). Dispensing is contingent on WBC and ANC test results.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1006802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory schizophrenia (FDA approved in adults); to reduce the risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CloZAPine may be confused with clonazePAM, cloNIDine, KlonoPIN&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clozaril&reg; may be confused with Clinoril&reg;, Colazal&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, ECG changes, hyper-/hypotension, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, akathisia, akinesia, anxiety, ataxia, confusion, depression, dizziness, drowsiness, fatigue, headache, insomnia, lethargy, myoclonic jerks, nightmares, restlessness, seizure, slurred speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, anorexia, constipation, diarrhea, heartburn, nausea, sialorrhea, throat discomfort, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary abnormalities (eg, abnormal ejaculation, retention, urgency, incontinence)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyper-/hypokinesia, pain, rigidity, spasm, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, tongue numbness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Amentia, amnesia, anemia, arrhythmia (atrial or ventricular), aspiration, blurred vision, bradycardia, bronchitis, cardiomyopathy (usually dilated), cataplexy, CHF, cholestasis, CPK increased, cyanosis, delirium, delusions, dermatitis, diabetes mellitus, difficult urination, DVT, dysphagia, eczema, edema, EEG abnormal, erythema multiforme, ESR increased, fecal impaction, gastric ulcer, gastroenteritis, granulocytopenia, hallucinations, hematemesis, hepatitis, hypercholesterolemia (rare), hyperglycemia, hypersensitivity reaction, hypertriglyceridemia (rare), hyperuricemia, hyponatremia, hyperosmolar coma, hypothermia, impotence, interstitial nephritis (acute), intestinal obstruction, jaundice, ketoacidosis, loss of speech, metabolic syndrome (Lamberti, 2006), MI, mitral valve  insufficiency, myasthenia syndrome, mydriasis, myocarditis, narrow-angle glaucoma, neuroleptic malignant syndrome, obsessive compulsive symptoms, palpitations, pancreatitis (acute), paralytic ileus, paresthesia, Parkinsonism, pericardial effusion, pericarditis, periorbital edema, phlebitis, photosensitivity, pleural effusion, pneumonia, priapism, pruritus, psychosis exacerbated, pulmonary embolism, rectal bleeding, respiratory arrest, rhabdomyolysis, salivary gland swelling, sepsis, status epilepticus, stroke, Stevens-Johnson syndrome, tardive dyskinesia, thrombocytopenia, thrombocytosis, thromboembolism, thrombophlebitis, torsade de pointes, urticaria, vasculitis, weight loss, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1006808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clozapine or any component; history of agranulocytosis or granulocytopenia with clozapine; uncontrolled epilepsy; severe CNS depression or comatose state; paralytic ileus; myeloproliferative disorders; use with other agents which have a well-known risk of agranulocytosis or bone marrow suppression",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5093228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased GI motility, paralytic ileus, urinary retention, benign prostatic hyperplasia, or visual problems. Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade; screening is recommended. Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade. Impaired core body temperature regulation may occur; use with caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia [may be as high as 15% in children and adolescents (Sporn, 2007)], and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics, and is dose-dependent; risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, this may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control. Patients with risk factors for diabetes should also be evaluated prior to therapy. Significant weight gain has been observed with clozapine; individual weight gain varies; monitor waist circumference and BMI. Use with caution in those at risk of aspiration pneumonia; dysphagia and esophageal dysmotility have been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Clozapine has been associated with benign, self-limiting fever (&lt;100.4&deg;F, usually within first 3 weeks). However, clozapine may also be associated with severe febrile reactions, including neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability. May be moderate to highly sedating; use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving general anesthesia (due to CNS effects). Rare cases of thromboembolism, including pulmonary embolism and stroke resulting in fatalities, have been associated with clozapine in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Clozapine is metabolized by CYP1A2, 2D6, and 3A4; use caution with medications which inhibit CYP activity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Concurrent use with benzodiazepines may increase the risk of severe cardiopulmonary reactions. Cigarette smoking may enhance the metabolism of clozapine. Use with caution in patients with hepatic disease or impairment; hepatitis has been reported as a consequence of therapy. Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Clozapine should not be stopped abruptly; taper off over 1-2 weeks. If conditions warrant abrupt discontinuation (leukopenia, myocarditis, cardiomyopathy), monitor patient for psychosis and cholinergic rebound (headache, nausea, vomiting, diarrhea).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Orally disintegrating tablets contain aspartame which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria.",
"     <b>",
"      Note:",
"     </b>",
"     The allowable intake for aspartame in adults is 50 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use caution when converting from brand to generic formulation; poor tolerability, including relapse, has been reported usually soon after product switch (1-3 months); monitor closely during this time (Bobo, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1006809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Potentially life-threatening agranulocytosis may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Due to the significant risk of agranulocytosis, it is strongly recommended that a patient must fail at least two trials of other primary medications for the treatment of schizophrenia (of adequate dose and duration) before initiating therapy with clozapine. Clozapine therapy should not be initiated in patients with WBC &lt;3500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or ANC &lt;2000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or history of myeloproliferative disorder, or clozapine induced agranulocytosis or granulocytopenia. WBC testing should occur periodically on an on-going basis (see prescribing information for monitoring details) to ensure that acceptable WBC/ANC counts are maintained. Initial episodes of moderate leukopenia or granulopoietic suppression confer up to a 12-fold increased risk for subsequent episodes of agranulocytosis. WBCs must be monitored weekly for at least 4 weeks after therapy discontinuation or until WBC is &ge;3500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and ANC is &ge;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Use with caution in patients receiving other marrow suppressive agents. Children and adolescents may be more sensitive to neutropenia compared to adults (Sporn, 2007); patients should be carefully monitored and counseled to report mouth sores, flu-like symptoms, or weakness. Eosinophilia has  been reported to occur with clozapine; interrupt therapy for total eosinophil count &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; may resume therapy when eosinophil count falls to &lt;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . The restricted distribution system ensures appropriate WBC and ANC monitoring.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Myocarditis, pericarditis, pericardial effusion, cardiomyopathy, CHF, ECG changes, arrhythmias, MI, and sudden death have also been reported with clozapine. Use clozapine with caution in patients with known cardiovascular or respiratory disease; carefully follow gradual dosage titration in these patients. Fatalities due to myocarditis have been reported; the highest incidence of fatal myocarditis occurs in the first month of therapy; however, later cases have also been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Myocarditis or cardiomyopathy should be considered in patients who present with signs/symptoms of heart failure (dyspnea, fatigue, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema), chest pain, palpitations, new ECG abnormalities (arrhythmias, ST-T wave abnormalities), or unexplained fever. Patients with tachycardia during the first month of therapy should be closely monitored for other signs of myocarditis. Discontinue clozapine if myocarditis is suspected; do not rechallenge in patients with clozapine-related myocarditis. The reported rate of myocarditis in clozapine-treated patients appears to be 17-322 times greater than in the general population.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause orthostatic hypotension (with or without syncope) and tachycardia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; collapse may rarely be profound and accompanied by respiratory and/or cardiac arrest; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (eg, patients with cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Collapse, respiratory arrest, and cardiac arrest during initiation of therapy have been reported in patients concurrently receiving benzodiazepines or other psychotropic drugs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Clozapine is associated with QT prolongation and ventricular arrhythmias including torsades de pointes; cardiac arrest and sudden death may occur. Use with caution in patients with: History of long QT syndrome, conditions which may increase the risk of QT prolongation (eg, cardiovascular disease, recent MI, uncompensated heart failure, clinically significant arrhythmias, family history of long QT syndrome), concomitant use of medications known to prolong the QT interval [eg, certain antipsychotic medications (ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, pimozide), certain antibiotics (erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), class Ia antiarrhythmics (quinidine, procainamide), class III antiarrhythmics (amiodarone, sotalol), or other medications known to prolong QT interval (pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron, probucol or tacrolimus)]. Hypokalemia and/or hypomagnesemia may increase the risk of QT prolongation; correct electrolyte abnormalities prior to initiating therapy. Discontinue clozapine if QT",
"     <sub>",
"      c",
"     </sub>",
"     interval &gt;500 msec.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Seizures have been associated with clozapine use in a dose-dependent manner",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Patients should be warned that a sudden loss of consciousness may occur with seizures.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     All of the above serious adverse effects have been reported in children and adolescents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature. An increased incidence of cerebrovascular adverse events (eg, transient ischemic attack, stroke), including fatalities, has been reported with the use of atypical antipsychotics in elderly patients with dementia-related psychosis. Clozapine is not approved for the treatment of patients with dementia-related psychosis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F153989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (moderate), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: May enhance the adverse/toxic effect of CloZAPine. Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the myelosuppressive effect of CloZAPine. CarBAMazepine may decrease the serum concentration of CloZAPine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of CloZAPine. Management: Consider use of an alternative H2 antagonist. Monitor for increased toxic effects of clozapine if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of CloZAPine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Myelosuppressive Agents: May enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: May decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5655253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect bioavailability.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F153923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F153938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not seen in animal studies. Clozapine crosses the placenta and can be detected in the fetal blood and amniotic fluid (Barnas, 1994). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. Healthcare providers are encouraged to enroll women 18-45 years of age exposed to clozapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry). Women with amenorrhea associated with use of other antipsychotic agents may return to normal menstruation when switching to clozapine therapy. Reliable contraceptive measures should be employed by women of childbearing potential switching to clozapine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1006843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Mental status, ECG, CBC (see below), liver function tests, vital signs, fasting lipid profile, and fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually, or as symptoms warrant); height, weight, BMI, personal/family history of obesity, waist circumference (weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals;  consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight); blood pressure, pulse, abnormal involuntary movement scale (AIMS).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     WBC and ANC should be obtained at baseline and at least weekly for the first 6 months of continuous treatment. If counts remain acceptable (WBC &ge;3500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ANC &ge;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) during this time period, then they may be monitored every other week for the next 6 months. If WBC/ANC continue to remain within these acceptable limits after the second 6 months of therapy, monitoring can be decreased to every 4 weeks. If clozapine is discontinued, a weekly WBC should be conducted for an additional 4 weeks or until WBC is &ge;3500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and ANC is &ge;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . If clozapine therapy is interrupted due to moderate leukopenia, weekly WBC/ANC monitoring is required for 12 months in patients restarted on clozapine treatment. If therapy is interrupted for reasons other than leukopenia/granulocytopenia, the 6-month time period for initiation of biweekly WBCs may need to be reset. This determination depends upon the treatment duration, the length of the break in therapy, and whether or not an abnormal blood event occurred. Consult manufacturer prescribing information for determination of appropriate WBC/ANC monitoring interval.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     Interrupt therapy for eosinophil count &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; may resume therapy when eosinophil count &lt;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1006826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clozapine (dibenzodiazepine antipsychotic) exhibits weak antagonism of  D",
"     <sub>",
"      1",
"     </sub>",
"     , D",
"     <sub>",
"      2",
"     </sub>",
"     , D",
"     <sub>",
"      3",
"     </sub>",
"     , and D",
"     <sub>",
"      5",
"     </sub>",
"     dopamine receptor subtypes, but shows high affinity for D",
"     <sub>",
"      4",
"     </sub>",
"     receptors; in addition, it blocks the serotonin (5HT",
"     <sub>",
"      2",
"     </sub>",
"     ), alpha-adrenergic, histamine H",
"     <sub>",
"      1",
"     </sub>",
"     , and cholinergic receptors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5093229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 1 week for sedation, improvement in sleep; 6-12 weeks for antipsychotic effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adequate trial: 6-12 weeks at a therapeutic dose and blood level",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 6-12 months; improvement may continue 6-12 months after clozapine initiation (Meltzer, 2003)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Duration: Variable",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1006828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97% to serum proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; forms metabolites with limited (desmethyl metabolite) or no activity (hydroxylated and N-oxide derivative derivatives).",
"     <b>",
"      Note:",
"     </b>",
"     A pediatric pharmacokinetic study (n=6; age: 9-16 years) found higher concentrations of the desmethyl metabolite in comparison to clozapine (especially in females) when compared to data from adult studies; the authors suggest that both the parent drug and desmethyl metabolite contribute to the efficacy and adverse effect profile in children and adolescents (Frazier, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 12% to 81% (not affected by food); orally disintegrating tablets are bioequivalent to the regular tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Steady state: 12 hours (range: 4-66 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Tablets: 2.5 hours (range: 1-6 hours); orally disintegrating tablets: 2.3 hours (range: 1-6 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~50% of dose) and feces (30%); trace amounts of unchanged drug  excreted in urine and feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1006847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/41/8854?source=see_link\">",
"      see \"Clozapine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use exactly as directed; do not increase dose or frequency. Do not discontinue this medication without consulting prescriber. If more than 2 days of medication are missed, do not restart at same dosage; contact physician for dosing instructions. Avoid alcohol, caffeine, other prescription, and nonprescription medications not approved by prescriber. Maintain adequate hydration unless instructed to restrict fluid intake. If you have diabetes, monitor blood glucose levels frequently. This medication may cause headache, excess drowsiness, dizziness, or blurred vision (use caution driving or when engaging in tasks requiring alertness until response to drug is known); constipation, diarrhea, dry mouth, nausea, vomiting, or postural hypotension (use caution climbing stairs or when changing position from lying or sitting to standing). This medication may decrease your white blood cell count (WBC); frequent blood tests are required to avoid serious adverse effects; due to low WBC, you may be prone to infections; report fever, sore throat, or other possible signs of infection. Report persistent CNS effects (insomnia, depression, altered consciousness), palpitations, rapid heartbeat, severe dizziness, vision change, hypersalivation, tearing, sweating, respiratory difficulty, or worsening of condition. Report seizures, flu-like symptoms, chest pain, shortness of breath, or excessive fatigue.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5655254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clozapine produces little or no prolactin elevation; this is in contrast to other more typical antipsychotic drugs",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alfaro CL, Wudarsky M, Nicolson R, et al, \"Correlation of Antipsychotic and Prolactin Concentrations in Children and Adolescents Acutely Treated With Haloperidol, Clozapine or Olanzapine,\"",
"      <i>",
"       J Child  Adolesc Psychopharmacol",
"      </i>",
"      , 2002, 12(2):83-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/12188977/pubmed\" id=\"12188977\" target=\"_blank\">",
"        12188977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, \"Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(2):596-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/14747245/pubmed\" id=\"14747245\" target=\"_blank\">",
"        14747245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker RW and Chengappa KN, \"Gastroesophageal Reflux as a Possible Result of Clozapine Treatment,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1998, 59(5):257",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/9632041/pubmed\" id=\"9632041\" target=\"_blank\">",
"        9632041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bobo WV, Stovall JA, Knostman M, et al, \"Converting From Brand-Name to Generic Clozapine: A Review of Effectiveness and Tolerability Data,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2010, 67(1):27-37.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Campellone JV, McCluskey LF, and Greenspan D, \"Fatal Outcome From Neuroleptic Malignant Syndrome Associated With Clozapine,\"",
"      <i>",
"       Neuropsychiatry, Neuropsychology, and Behavioral Neurology",
"      </i>",
"      , 1995, 8:70-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Correll CU, Penzner JB, Parikh UH, et al, \"Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents,\"",
"      <i>",
"       Child Adolesc Psych Clin N Am",
"      </i>",
"      , 2006, 15(1):177-206.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/16321730/pubmed\" id=\"16321730\" target=\"_blank\">",
"        16321730",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, Frazier JA, Gerbino-Rosen B, et al, \"Is There a Role for Clozapine in the Treatment of Children and Adolescents?\"",
"      <i>",
"       J Am Acad Child Adolesc Psych",
"      </i>",
"      , 2007, 46(3):423-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/17314729/pubmed\" id=\"17314729\" target=\"_blank\">",
"        17314729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frazier JA, Cohen LG, Jacobsen L, et al, \"Clozapine Pharmacokinetics in Children and Adolescents With Childhood-Onset Schizophrenia,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2003,  23(1):87-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/12544379/pubmed\" id=\"12544379\" target=\"_blank\">",
"        12544379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Funderberg LG, Vertrees JE, True JE, et al, \"Seizure Following Addition of Erythromycin to Clozapine Treatment,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1840-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/7977898/pubmed\" id=\"7977898\" target=\"_blank\">",
"        7977898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerbino-Rosen G, Roofeh D, Tompkins DA, et al, \"Hematological Adverse Events in Clozapine-Treated Children and Adolescents,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2005, 44(10):1024-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/16175107/pubmed\" id=\"16175107\" target=\"_blank\">",
"        16175107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerson SL and Meltzer H, \"Mechanisms of Clozapine-Induced Agranulocytosis,\"",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1992, 7(Suppl 1):17-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/1503673/pubmed\" id=\"1503673\" target=\"_blank\">",
"        1503673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hagg S, Spigset O, and Soderstrom TG, \"Association of Venous Thromboembolism and Clozapine,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 355(9210):1155-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/10791380/pubmed\" id=\"10791380\" target=\"_blank\">",
"        10791380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kane J, Honigfeld G, Singer J, et al, \"Clozapine for the Treatment-Resistant Schizophrenic. A Double-Blind Comparison With Chlorpromazine,\"",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 1988, 45(9):789-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/3046553/pubmed\" id=\"3046553\" target=\"_blank\">",
"        3046553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kant R, Chalansani R, Chengappa KN, et al, \"The Off-Label Use of Clozapine in Adolescents With Bipolar Disorder, Intermittent Explosive Disorder, or Posttraumatic Stress Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2004, 14(1):57-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/15142392/pubmed\" id=\"15142392\" target=\"_blank\">",
"        15142392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kranzler HN, Kester HM, Gerbino-Rosen G, et al, \"Treatment-Refractory Schizophrenia in Children and Adolescents: An Update on Clozapine and Other Pharmacologic Interventions,\"",
"      <i>",
"       Child Adolesc Psychiatr Clin N Am",
"      </i>",
"      , 2006, 15(1):135-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/16321728/pubmed\" id=\"16321728\" target=\"_blank\">",
"        16321728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kranzler H, Roofeh D, Gerbino-Rosen G, et al, \"Clozapine: Its Impact on Aggressive Behavior Among Children and Adolescents With Schizophrenia,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2005,  44(1):55-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/15608544/pubmed\" id=\"15608544\" target=\"_blank\">",
"        15608544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumra S, Frazier JA, Jacobsen LK, et al, \"Childhood-Onset Schizophrenia. A Double-Blind Clozapine-Haloperidol Comparison,\"",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 1996, 53(12):1090-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/8956674/pubmed\" id=\"8956674\" target=\"_blank\">",
"        8956674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lamberti JS, Olson D, Crilly JF, et al, \"Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2006, 163(7):1273-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/16816234/pubmed\" id=\"16816234\" target=\"_blank\">",
"        16816234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mady SP and Wax P, \"Clozapine Intoxication in a Young Child,\"",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1993, 35(4):338.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCarthy RH and Terkelsen KG, \"Esophageal Dysfunction in Two Patients After Clozapine Treatment,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1994, 14(4):281-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/7962688/pubmed\" id=\"7962688\" target=\"_blank\">",
"        7962688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meltzer HY, Alphs L, Green AI, et al, \"Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT),\"",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 2003, 60(1):82-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/12511175/pubmed\" id=\"12511175\" target=\"_blank\">",
"        12511175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pacia SV and Devinsky O, \"Clozapine-Related Seizures: Experience With 5629 Patients,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1994, 44(12):2247-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/7991106/pubmed\" id=\"7991106\" target=\"_blank\">",
"        7991106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Radford JM, Brown TM, and Borison RL, \"Unexpected Dystonia While Changing From Clozapine to Risperidone,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1995, 15(3):225-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/7543499/pubmed\" id=\"7543499\" target=\"_blank\">",
"        7543499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw P, Sporn A, Gogtay N, et al, \"Childhood-Onset Schizophrenia: A Double-Blind, Randomized, Clozapine-Olanzapine Comparison,\"",
"      <i>",
"       Arch Gen Psych",
"      </i>",
"      , 2006, 63(7):721-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/16818861/pubmed\" id=\"16818861\" target=\"_blank\">",
"        16818861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sporn AL, Vermani A, Greenstein DK, et al, \"Clozapine Treatment of Childhood-Onset Schizophrenia: Evaluation of Effectiveness, Adverse Effects, and Long-Term Outcome,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(10):1349-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/17885577/pubmed\" id=\"17885577\" target=\"_blank\">",
"        17885577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Testani M, \"Clozapine-Induced Orthostatic Hypotension Treated With Fludrocortisone,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1994, 55(11):497-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/7989286/pubmed\" id=\"7989286\" target=\"_blank\">",
"        7989286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheatley M, Plant J, Reader H, et al, \"Clozapine Treatment of Adolescents With Posttraumatic Stress Disorder and Psychotic Symptoms,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2004, 24(2):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/15206664/pubmed\" id=\"15206664\" target=\"_blank\">",
"        15206664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson WH and Claussen AM, \"Seizures Associated With Clozapine Treatment in a State Hospital,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1994, 55(5):184-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/31/13817/abstract-text/8071267/pubmed\" id=\"8071267\" target=\"_blank\">",
"        8071267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12995 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13817=[""].join("\n");
var outline_f13_31_13817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708679\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153952\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153953\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006801\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006835\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153928\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153912\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16156266\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11218426\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006841\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006824\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006802\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154003\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154001\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006808\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093228\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006809\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153989\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153921\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5655253\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153923\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153938\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006843\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006826\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093229\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006828\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006847\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5655254\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=related_link\">",
"      Clozapine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/41/8854?source=related_link\">",
"      Clozapine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_31_13818="Triple antithrombotic therapy in patients with cardiovascular disease";
var content_f13_31_13818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Triple antithrombotic therapy in patients with cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/31/13818/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13818/contributors\">",
"     Nikolaus Sarafoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13818/contributors\">",
"     David R Holmes, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/31/13818/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13818/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13818/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/31/13818/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/31/13818/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/31/13818/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concomitant use of dual antiplatelet therapy (DAT) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor blocker and oral anticoagulation (OAC) is necessary in some patients with cardiovascular disease. This is referred to as triple oral antithrombotic therapy (TOAT).",
"   </p>",
"   <p>",
"    DAT is required for months or perhaps years after either coronary artery stenting or acute coronary syndrome (ACS) and OAC is necessary for the prevention and treatment of thromboembolic events in many patients with atrial fibrillation, mechanical heart valves, or venous thromboembolic disease. However, the decision to initiate TOAT must take into consideration an increased rate of bleeding events compared to lesser antithrombotic therapy, while premature or temporary discontinuation of either DAT or OAC places these patients at risk of either stent thrombosis or stroke. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Rates'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who require TOAT are not uncommon. It is estimated that between five and ten percent of patients scheduled for percutaneous coronary intervention (PCI) have been on OAC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition as the population ages, the prevalence of atrial fibrillation (the principal indication for anticoagulation) will increase. Many of these will need DAT for either ACS or stenting, increasing the pool of patients who require TOAT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the risks and benefits of TOAT, as well as the prevention of bleeding in these patients, as well as address the following two critically important clinical questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving oral anticoagulant therapy, does the addition of DAT either eliminate the need for or allow for a reduction in the dosing of the anticoagulant?",
"     </li>",
"     <li>",
"      For patients receiving DAT, does the addition of oral anticoagulant therapy eliminate the need for or duration of treatment with one or both antiplatelet therapies?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications for either DAT or OAC are briefly mentioned but are discussed extensively elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DAT after stent implantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"       \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DAT after an acute coronary syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OAC for atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OAC in patients with mechanical heart valves. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"       \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OAC in patients with venous thromboembolism, such as deep vein thrombosis and pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link\">",
"       \"Anticoagulation in acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"       \"Treatment of lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OAC to prevent and treat left ventricular thrombi. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=see_link\">",
"       \"Left ventricular thrombus after acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20425?source=see_link&amp;anchor=H18#H18\">",
"       \"Chronic anticoagulation after acute coronary syndromes\", section on 'Recommendations of others'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OAC and heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"       \"Indications for antithrombotic therapy in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TOAT VERSUS OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnoses for which either OAC or DAT are indicated are listed above. The simultaneous use of both therapies (TOAT) is reasonable and often necessary in many patients who have more than one of these diagnoses, as DAT is less effective in preventing stroke than OAC and OAC plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (without thienopyridine) is insufficient to prevent stent thrombosis (ST) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H19#H19\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Aspirin plus clopidogrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence that can be used to formulate recommendations for the optimal antithrombotic strategy in patients with indications for OAC and DAT is not robust and includes only one published randomized trial (WOEST).",
"   </p>",
"   <p>",
"    Some evidence of benefit from TOAT comes from studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and ximelagatran [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     TOAT versus DAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following represent the range of findings in observational studies that compared TOAT and DAT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 426 patients with atrial fibrillation (AF) undergoing PCI, DAT was prescribed in 41 and TOAT in 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/5\">",
"       5",
"      </a>",
"      ]. Non-anticoagulation was associated with increased mortality (28 versus 18 percent; hazard ratio [HR] 3.43, 95% CI 1.61-7.54).",
"     </li>",
"     <li>",
"      In a propensity matching study of 604 registry patients with AF undergoing PCI, OAC prescription at discharge was associated with a lower rate of major adverse cardiovascular events (HR 0.40, 95% CI 0.22-0.74) and all-cause mortality (0.34, 95% CI 0.17-0.69) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study 239 patients on OAC (AF was the indication for OAC in the majority) who underwent PCI, patients who were on DAT, compared to patients on TOAT, had a significantly higher rate of stroke (8.8 percent versus 2.8 percent) and ST (5.9 versus 1.9 percent) respectively at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/7\">",
"       7",
"      </a>",
"      ]. As expected, patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      had a higher incidence of ST compared to those on TOAT (15.2 percent versus 1.9 percent).",
"     </li>",
"     <li>",
"      Two studies have shown no significant difference in major adverse cardiovascular outcomes. In the first, of the 515 patients on OAC who underwent PCI with drug eluting stents (DES), 60 percent were discharged on TOAT and 40 percent on DAT [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/8\">",
"       8",
"      </a>",
"      ]. There was no significant difference in the development of major adverse cardiovascular events of the two groups respectively during the required period of DAT (4.2 and 7.2 percent; odds ratio [OR] 0.61, 95% CI 0.29-01.28) or at two years (14.1 and 18.0 percent; OR 0.76, 95% CI 0.48-01.21). In the second study, there was no significant difference in the rates of major adverse cardiovascular events in 132 AF patients on OAC at low thromboembolic risk (CHADS2 score &lt;2) who underwent PCI [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link&amp;anchor=H3#H3\">",
"       \"Risk of embolization in atrial fibrillation\", section on 'Incidence of embolism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that major adverse cardiovascular outcomes are worse in patients with an indication for OAC who undergo PCI and are not discharged on TOAT. However, firm conclusions should not be based on these observational studies in which the possibility of bias is high.",
"   </p>",
"   <p>",
"    Two further points need to be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The above studies do not exclude the possibility that patients at low risk for thromboembolic events, such as those with atrial fibrillation and a CHADS2 score of less than 2, could have OAC discontinued with reasonable safety during the period of DAT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H19#H19\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Aspirin plus clopidogrel'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most of the patients on TOAT included in the above studies had atrial fibrillation as the reason for OAC. Thus, in this setting, there is little evidence upon which decisions can be made for patients on OAC with other diagnoses, such as valvular heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TOAT versus OAC plus a single antiplatelet agent",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22848168\">",
"    <span class=\"h3\">",
"     After stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;DAT with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker has been shown to be more effective than the combination of aspirin and OAC for preventing cardiovascular events after coronary stent placement and is currently the recommended antithrombotic regimen after PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of whether OAC plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is as efficacious as TOAT was evaluated in the open-label WOEST trial, which randomly assigned 573 patients who were receiving long-term oral anticoagulant and undergoing PCI to clopidogrel alone or clopidogrel plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (TOAT) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/10\">",
"     10",
"    </a>",
"    ]. In the TOAT group, patients received aspirin 80 mg daily and clopidogrel 75 mg daily for at least one month after bare metal stenting (up to one year for patients with acute coronary syndrome) and for at least one year after drug-eluting stenting (DES). In the oral anticoagulation and clopidogrel group, patients receive clopidogrel 75 mg daily for at least one month after bare metal stenting (up to one year for patients with acute coronary syndrome) and for at least one year after DES. Antithrombotic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    was not used. After a median follow-up of 358 days, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The indication for anticoagulant was atrial fibrillation in 69 percent of patients. The rates of radial and femoral access were 27 and 73 percent, respectively. DES were used in approximately 65 percent of cases.",
"     </li>",
"     <li>",
"      The primary end point of bleeding was significantly lower in the group assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . This issue is discussed in detail below.",
"     </li>",
"     <li>",
"      The combined secondary end point of death, myocardial infarction, stoke, target-vessel revascularization, and stent thrombosis was lower in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      group (11.1 versus 17.6 percent; adjusted hazard ratio 0.56, 95% CI 0.35-0.91), as was the secondary end point of all-cause death (2.5 versus 6.3 percent; adjusted hazard ratio 0.39, 95% CI 0.16-0.93).",
"     </li>",
"     <li>",
"      The study was not powered to determine if the omission of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      significantly impacted the rates of definite stent thrombosis (0.4 versus 1.1 percent in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      plus anticoagulant and TOAT groups, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    WOEST suggests that for many patients who require both anticoagulant and antiplatelet therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may not be necessary and perhaps harmful. However, the WOEST trial was small (only 279 patients received oral anticoagulant plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and of these only about 180 received a drug-eluting stent [DES]) and not designed or powered to detect stent thrombosis risk. Since it is possible that the omission of aspirin may lead to an increased risk of stent thrombosis (particularly after DES), we are reluctant to recommend this strategy. Larger studies in this area are needed. &nbsp;",
"   </p>",
"   <p>",
"    TOAT has also been compared to OAC plus a single antiplatelet agent in the following two observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective registry of 405 patients on OAC who underwent PCI, CV events occurred significantly more frequently in the group that received OAC plus one antiplatelet agent (15.2 percent) as compared with patients receiving triple (7.9 percent) or DAT (1.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/9\">",
"       9",
"      </a>",
"      ]. There was no difference in bleeding events between patients treated with triple versus OAC plus one antiplatelet agent (15.5 percent versus 13.0 percent). Whether the single antiplatelet was",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was not reported in this study.",
"     </li>",
"     <li>",
"      Another study of 239 patients on OAC who underwent PCI found that those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      had the highest incidence of ST (15.2 percent versus 1.9 percent for triple therapy) and MI (18.2 percent versus 8.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/7\">",
"       7",
"      </a>",
"      ]. The rate of stroke was highest among those discharged on aspirin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , but no warfarin. No difference was observed in major bleeding (6.1 percent versus 6.6 percent). For patients receiving clopidogrel plus warfarin as compared with triple therapy, there was no difference in ST (0 percent versus 1.9 percent) or MI (11.1 percent versus 8.5 percent), although the study did not have adequate power to detect these potentially clinically significant differences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until further evidence is available to help guide decision making, we believe TOAT, as opposed to anticoagulant plus single antiplatelet agent, should be recommended to patients with stent placement and an indication for oral anticoagulant. This recommendation is based on our concern about the potential for coronary artery stent thrombosis. For patients at very high bleeding risk, we believe it is reasonable to omit",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    based on results from the WOEST trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22848175\">",
"    <span class=\"h3\">",
"     ACS patients treated medically",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute coronary syndrome (ACS) patients who do not undergo revascularization are generally treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a P2Y12 receptor blocker (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no prospective studies of TOAT compared with OAC plus one antiplatelet agent (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) in non-stented acute coronary syndrome (ACS) patients who require OAC. We prefer oral anticoagulant plus aspirin (instead of TOAT) in such patients. The rationale for our recommendation is the relatively modest reduction in the rate of MI seen with DAT compared to aspirin alone in the CURE trial and the evidence that oral anticoagulation may add to the efficacy of aspirin alone in patients (on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) whose international normalized ratio is kept in the 2.0-3.0 range. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20425?source=see_link&amp;anchor=H4#H4\">",
"     \"Chronic anticoagulation after acute coronary syndromes\", section on 'Meta-analyses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are at low risk of bleeding (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1258?source=see_link&amp;anchor=H10#H10\">",
"     \"Anticoagulation in older adults\", section on 'Risk of bleeding'",
"    </a>",
"    ) and are particularly concerned about recurrent ischemic events, TOAT is a reasonable option.",
"   </p>",
"   <p>",
"    The long-term approach to such patients is presented below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Long-term antithrombotic therapy after TOAT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Practice patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series have evaluated antithrombotic regimens chosen by cardiologists for patients with indications for both anticoagulant therapy (usually atrial fibrillation) and DAT (PCI with stenting or ACS) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/5,9,11\">",
"     5,9,11",
"    </a>",
"    ]. The largest reported series comes from the CRUSADE registry that evaluated discharge antithrombotic regimens in 5673 patients previously on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/12\">",
"     12",
"    </a>",
"    ]. At discharge, 24 percent of patients were not on warfarin. Among the subset of 1247 patients who underwent PCI with stenting, 60 percent received TOAT, 31 percent were on DAT without warfarin, and 3 percent were on warfarin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;High quality evidence demonstrating better outcomes with TOAT than with other antithrombotic regimens in patients who have a long-term requirement for OAC after PCI is lacking. We believe that TOAT should be given to minimize the risks of stent thrombosis and cerebrovascular emboli. As the amount of time after PCI increases, the risk of stent thrombosis falls and the rates of emboli and bleed stay relatively constant. The point at which the risks of TOAT outweigh its benefits is unknown. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Duration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BLEEDING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66050976\">",
"    <span class=\"h2\">",
"     Risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the individual patient, the risk of bleeding is determined by many factors. Major risk factors include age &ge;65 years, prior history of bleeding, and hypertension. Risk prediction models are available (",
"    <a class=\"graphic graphic_table graphicRef75259 \" href=\"UTD.htm?38/14/39148\">",
"     table 1",
"    </a>",
"    ). This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use of warfarin\", section on 'Major risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main concern of TOAT is the risk of bleeding. Information about the increase in absolute and relative risks of bleeding associated with TOAT compared to other antithrombotic regimens comes from the WOEST trial (see",
"    <a class=\"local\" href=\"#H4\">",
"     'TOAT versus OAC plus a single antiplatelet agent'",
"    </a>",
"    above) as well as observational studies and a systematic review of them [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/2,5,7-9,13-19\">",
"     2,5,7-9,13-19",
"    </a>",
"    ]. Estimating risk from these studies is complicated by the fact that the comparator therapies varied widely in agent(s), duration, and dose; some of the studies included control groups that had no indication for OAC. For instance, these studies present a broad range in the relative risk of bleeding for patients with TOAT compared to those on DAT, with as much as a 5 percent absolute decrease to an 11 percent absolute increase [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, bleeding definitions differ across all studies with many using the major bleeding definition of the TIMI study group (intracranial bleeding or clinically significant overt signs of hemorrhage associated with &gt;5.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    decrease in hemoglobin level) (",
"    <a class=\"graphic graphic_table graphicRef71353 \" href=\"UTD.htm?28/0/28684\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/1\">",
"     1",
"    </a>",
"    ]. Others incorporated the need for transfusion of two or more units of blood, the need for corrective surgery, or the occurrence of retroperitoneal hemorrhage into their bleeding definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/5,7,9\">",
"     5,7,9",
"    </a>",
"    ]. Another study defined major bleeding as a symptomatic event that was associated with a decrease in hemoglobin of at least 2.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/13\">",
"     13",
"    </a>",
"    ]. Some use the more recent BARC definition (",
"    <a class=\"graphic graphic_table graphicRef77838 \" href=\"UTD.htm?11/37/11869\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the WOEST trial (see",
"    <a class=\"local\" href=\"#H4\">",
"     'TOAT versus OAC plus a single antiplatelet agent'",
"    </a>",
"    above), which randomly assigned patients undergoing PCI and taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or clopidogrel plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , bleeding episodes (any) occurred less frequently in those receiving oral anticoagulation than those receiving TOAT (19.4 versus 44.4 percent; hazard ratio 0.36, 95% CI 0.26-0.50) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, TIMI major bleeding and BARC type 3 bleeding occurred less frequently (3.2 versus 5.6 percent and 6.5 versus 12.7 percent).",
"   </p>",
"   <p>",
"    The best available observational data come from a retrospective analysis assessing the risk of bleeding in 118,606 patients with atrial fibrillation treated with different combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and vitamin K antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/20\">",
"     20",
"    </a>",
"    ]. During a mean follow-up of 3.3 years, 11.4 percent of patients experienced a nonfatal (10.3 percent) or fatal (1.2 percent) bleeding. The yearly incidence of bleeding was 3.7 percent for patients on aspirin alone, 5.6 percent for clopidogrel alone, 3.9 percent for OAC alone, 7.4 percent for DAT, 6.9 percent for aspirin and OAC, 13.9 percent for clopidogrel and OAC, and 15.7 percent for TOAT. Using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    as the reference, the adjusted hazard ratios for bleeding were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      : 1.06, 95% CI 0.9-1.3",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      : 0.93, 95% CI 0.9-0.98",
"     </li>",
"     <li>",
"      DAT: 1.66, 95% CI 1.3-2.0",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      and OAC: 1.83, 95% CI 1.7-1.96",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      and OAC: 3.08, 95% CI 2.3-3.9",
"     </li>",
"     <li>",
"      TOAT: 3.70, 95% CI 2.9-4.8",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on available studies, we believe the following are reasonable estimates of bleeding risk for patients on TOAT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a two- to fivefold increase in bleeding risk compared to patients on DAT [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/2,17,18,20\">",
"       2,17,18,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combined major and minor bleeding rate for patients on TOAT ranges from 9 to 27 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/5,13,15,16\">",
"       5,13,15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative rates of bleeding in patients taking oral anticoagulant and one antiplatelet agent is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H27#H27\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Patients on long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Outcomes after bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong relationship of 30 day bleeding after PCI and one-year mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/21\">",
"     21",
"    </a>",
"    ]. Bleeding events are not only a predictor of mortality, but also have an impact on the compliance of patients with their medication. Even the occurrence of minimal bleeding events, such as easy bruising or bleeding from small cuts, is of high importance as it has been demonstrated that the incidence of such \"nuisance\" bleeding is associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy cessation in 11.1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/22\">",
"     22",
"    </a>",
"    ]. As premature discontinuation of clopidogrel is associated with an increased rate of ST, non-compliance or discontinuation may contribute to the mortality risk associated with bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following measures may decrease the risk of bleeding in patients on triple therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing of the administered antithrombotic drugs should be kept as low as possible.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    may be given at &le;100 mg daily, as it has been demonstrated in patients receiving DAT after PCI that low-dose aspirin appeared to be as effective as higher doses in preventing ischemic events, and was also associated with a lower rate of major bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Management of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current guidelines recommend that the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dosage should be titrated to the lowest possible international normalized ratio (INR) level in patients receiving triple therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/24\">",
"     24",
"    </a>",
"    ]. It has been shown that this will significantly reduce the risk for bleeding in patients on triple therapy without losing the efficacy to prevent thromboembolic events. One study demonstrated that aiming for a target INR of 2.0 to 2.5 leads to a significant decrease in bleeding events in patients treated with triple therapy as compared with INR levels &gt;2.6. The patients treated with an INR level of 2.0 to 2.5 had similar bleeding events compared with DAT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/25\">",
"     25",
"    </a>",
"    ]. Another study has shown that an INR of 2.5 to 3.0 in patients with mechanical valves, and an INR of 2.0 to 2.5 for all other indications leads to comparable rates of major bleeding in patients with triple therapy compared with DAT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/8\">",
"     8",
"    </a>",
"    ]. We recommend that the frequency of laboratory tests should be increased to safely maintain the INR levels in this lower range. There is insufficient evidence to support an INR lower than recommended targets in patients on TOAT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, health care providers caring for patients on TOAT should be aware of and, when appropriate, discuss with their patients the most potent risk factors for erratic INR control such as decompensated heart failure, protracted new use of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=see_link&amp;anchor=H7#H7\">",
"     \"Outpatient management of oral anticoagulation\", section on 'Importance of strict INR control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;While shorter periods of DAT than are recommended for patients without a need for anticoagulation may decrease bleeding rates without significantly increasing adverse cardiovascular outcomes, there are no high-quality data to support this. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'DES versus BMS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gastroprotective therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As 30 to 40 percent of hemorrhagic events in patients on triple therapy occur in the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/27\">",
"     27",
"    </a>",
"    ], reducing the risk of gastrointestinal bleeding is relevant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=see_link&amp;anchor=H5971563#H5971563\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Incidence and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion of the role of gastroprotective therapy in patients taking multiple antithrombotic drugs is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H10#H10\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Possible adverse effect of proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A discussion of the role of prophylactic proton pump inhibitors in patients with acute coronary syndromes is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the non-acute management of ST elevation myocardial infarction\", section on 'Gastrointestinal prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Gastrointestinal prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of the primary prevention of gastrointestinal bleeding in patients taking long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H8#H8\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Primary prevention of aspirin induced GI bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential benefit of H. pylori eradication is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H7#H7\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Role of Helicobacter pylori'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following measures may be of additional benefit in the prevention of major bleeding in patients receiving TOAT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attention to blood pressure control (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Warn the patient regarding the use of over-the-counter nonsteroidal antiinflammatory drugs, including those that contain",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"     </li>",
"     <li>",
"      Consideration of a physical",
"      <span class=\"nowrap\">",
"       therapy/safety",
"      </span>",
"      evaluation before discharge to minimize fall risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PERIPROCEDURAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of how to manage a patient on oral anticoagulation who needs to undergo cardiac catheterization and possible percutaneous coronary intervention is complicated. Either the urgency of the procedure or the degree of risk for stopping oral anticoagulation can influence decision making. Our approach is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H32#H32\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Patients who require warfarin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link&amp;anchor=H27#H27\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\", section on 'Interruption of warfarin for cardiac catheterization/angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Periprocedural bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo catheterization on OAC, as opposed to those not on OAC, have a higher frequency of periprocedural bleeding, including periprocedural gastrointestinal bleeding. The risk factors for periprocedural bleeding in these patients are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=see_link&amp;anchor=H4#H4\">",
"     \"Periprocedural bleeding in patients undergoing percutaneous coronary intervention\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=see_link\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those patients who remain on OAC, a radial access approach should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H23#H23\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Vascular complications'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     DES versus BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The length of antithrombotic treatment differs with the type of stent that is used. The minimal treatment regimen after bare-metal stent (BMS) implantation is four weeks, while after drug eluting stent (DES) implantation, the current recommendation for DAT is at least 12 months unless the patient is at high risk for bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H18#H18\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only study that has compared outcomes of anticoagulated patients undergoing PCI with either BMS or DES found that the latter was associated with a significantly increased risk of major bleeding (2.3 percent versus 1.2 percent 10,000 days of exposure) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence density of MACE as well as the incidence of all-cause mortality in both groups were similar.",
"   </p>",
"   <p>",
"    A higher risk of major bleeding with DES in comparison with BMS raises the possibility that DES should be limited to lesions with a high risk of restenosis, such as small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    long lesions, or patients with diabetes.",
"   </p>",
"   <p>",
"    Weighing the bleeding risk against the possible risk of ST in this patient population is a difficult task. An observational study has shown that ST occurs mostly early after the procedure, while the incidence of bleeding may not diminish with time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/7\">",
"     7",
"    </a>",
"    ]. The superiority of DAT over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in the first four weeks after stent implantation has been sufficiently shown in numerous studies and points to the requirement for DAT with OAC when indicated during this interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue for longer-term DAT as recommended after DES is more difficult. The relative benefit of DAT versus OAC or OAC plus single agent anti-platelet therapy for prevention of late stent thrombosis or bleeding complications is not well established. The benefit of DES versus BMS for prevention of restenosis must be balanced against the increased late risk for bleeding with a minimum of 12 months of triple therapy. The optimal duration of TOAT in DES treated patients is currently under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are currently no data as to whether OAC and one antiplatelet agent may offer protection against late ST (30 days to one year). It has been proposed that limiting triple therapy to three months and continuing thereafter with ASA and OAC in patients receiving a DES may avoid excessive bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in patients who have suffered from ST in the past, shortening of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy is not advisable.",
"   </p>",
"   <p>",
"    In order to minimize the duration of thienopyridine therapy in patients who have a long-term requirement for oral anticoagulation, we recommend using bare-metal as opposed to drug-eluting stents when there is a low risk for restenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LONG-TERM ANTITHROMBOTIC THERAPY AFTER TOAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal antithrombotic regimen after one year for patients who have received TOAT for some duration has not been well studied. Patients who have had an acute coronary syndrome are considered to have stable coronary artery disease after one year and thus have no clear indication for prolonged dual antiplatelet therapy (DAT). We suggest not routinely adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (or other antiplatelet agent) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (or other anticoagulant) to reduce the risk of ischemic cardiovascular disease events in patients with or at high risk for cardiovascular disease",
"    <strong>",
"     who have not been stented",
"    </strong>",
"    . There is no convincing evidence of benefit and the risk of major bleeding with combined therapy is higher. This recommendation is consistent with that made in the 2012 American College of Chest Physicians (ACCP) Antithrombotic Therapy and Prevention of Thrombosis guideline on Antithrombotic therapy for atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/29\">",
"     29",
"    </a>",
"    ]. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H611366894#H611366894\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Anticoagulated patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For stented patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and at least one antiplatelet agent are given for at least one year. In the broad population of stented patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is continued indefinitely, both for secondary prevention and the prevention of episode of very late stent thrombosis. For stented patients with indications for aspirin plus warfarin (such as those with atrial fibrillation), there is limited evidence comparing the efficacy of anticoagulation alone to that with anticoagulation plus warfarin. An increase in bleeding with two antithrombotic agents, compared to one, is well established. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Rates'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who have received drug-eluting stents, our experts suggest continuing indefinite",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy, as opposed to continuing warfarin alone, after the required duration of TOAT. This recommendation to continue aspirin after the required period for TOAT differs from that of the ACCP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/30\">",
"     30",
"    </a>",
"    ]. For patients who have received a bare-metal stent, OAC alone may be reasonable alternative, particularly if the risk of bleeding is increased. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Major society guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This recommendation to continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (plus anticoagulation) in patients who have been stented is based on the observation of a continued risk of stent thrombosis after one year and the lack of evidence showing that anticoagulation alone is an effective preventative strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NEWER ANTITHROMBOTIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Alternatives to clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    is an essential component in the treatment of ACS and after coronary stent placement, because it significantly improves the outcomes. However, clopidogrel has at least three drawbacks: Delayed onset of action, large interindividual variability in platelet response, and irreversibility of its inhibitory effect on platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/31\">",
"     31",
"    </a>",
"    ]. This has led to the development of newer agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    which have been studied in the setting of acute coronary syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=see_link&amp;anchor=H12#H12\">",
"     \"Platelet biology\", section on 'Prasugrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=see_link&amp;anchor=H13#H13\">",
"     \"Platelet biology\", section on 'Other P2Y12 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are currently no data on a combined triple therapy of these agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and OAC. As the bleeding rate in published series is higher with prasugrel than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , it is unlikely that this agent will be considered for patients on TOAT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H22#H22\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Prasugrel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Alternatives to warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with atrial fibrillation who require TOAT,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    , and possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    may be preferable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for the prevention or treatment of thromboembolic events. Warfarin has two major limitations: a narrow therapeutic window of adequate anticoagulation without bleeding and a highly variable dose-response relation among individuals that requires monitoring by international normalized ratio (INR) testing. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    ). Newer anticoagulants, such as factor Xa inhibitors (for example rivaroxaban and apixaban) and the direct thrombin inhibitors (such as dabigatran) may overcome the limitations of warfarin. These are discussed extensively elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Large randomized trials have compared the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    compared to adjusted-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients with atrial fibrillation. These trials are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H524842274#H524842274\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Direct thrombin and factor Xa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the RE-LY and ARISTOTLE trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    at the 110 mg dose and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    at the 5 mg dose (respectively) were found to have a significantly lower incidence of major bleeding than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (as well as equal or better efficacy, respectively). This benefit was confirmed (at an abstract presentation during the 2011 European Society of Cardiology Congress) in the subgroup of patients taking dual antiplatelet therapy in RE-LY [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/32\">",
"     32",
"    </a>",
"    ]. In the ROCKET-AF trial, there was not a statistically significant difference in the rates of major bleeding or ischemic outcomes between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and warfarin.",
"   </p>",
"   <p>",
"    Based on the results of these three randomized trials, we make the following suggestions for the choice of oral anticoagulant in patients who require TOAT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and whose INR has been relatively easy to maintain within the 2.0 to 3.0 range (for atrial fibrillation), we suggest continuing with warfarin. During the period of triple antithrombotic therapy, the INR should be monitored closely. For patients previously on warfarin whose INRs have been difficult to manage or in whom the risk of bleeding is thought to be high, switching to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      110 mg dose or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      5 mg (both twice daily) may be reasonable.",
"     </li>",
"     <li>",
"      For patients on dual antiplatelet therapy who need initiation of oral anticoagulant therapy to prevent embolization in atrial fibrillation, we suggest choosing (based on availability) either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      at the 110 mg dose or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      5 mg (both twice daily) in preference to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for percutaneous coronary intervention, ST-elevation myocardial infarction, and atrial fibrillation agree on the following recommendations regarding triple therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/24,29,33,34\">",
"     24,29,33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The INR should be monitored closely in patients on TOAT due to the increased risk of bleeding. The recommended INR range is 2.0 to 2.5 for patients with atrial fibrillation requiring TOAT after PCI [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      (acetylsalicylic acid - 75 mg to 81 mg, and perhaps higher according to the ESC) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75 mg are the recommended daily doses of the antiplatelet agents [",
"      <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines have not made a recommendation regarding the duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy in patients on TOAT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The consensus document of the European Society of Cardiology (ESC) working group on thrombosis entitled \"Antithrombotic management of atrial fibrillation in patients presenting with acute coronary syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    undergoing coronary stenting\" addresses this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/30\">",
"     30",
"    </a>",
"    ], and their recommendations have been incorporated in the recent atrial fibrillation guidelines of the ESC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/34\">",
"     34",
"    </a>",
"    ]. This document makes the following recommendations, each of which is followed by long-term OAC alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For elective procedures in patients at low or intermediate bleeding risk who receive bare-metal stents (BMS): TOAT for one month, followed by up to 12 months with OAC with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For elective procedures in patients at low or intermediate bleeding risk who receive drug-eluting stents (DES): TOAT for three months with -olimus and six months with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      DES. After this initial period, up to 12 months of OAC with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For procedures in ACS patients at low to intermediate bleeding risk (only BMS are recommended): TOAT for six months. After this initial period, up to 12 months of OAC with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For elective procedures in patients at high bleeding risk (only BMS): TOAT for two to four weeks.",
"     </li>",
"     <li>",
"      For urgent procedures in ACS patients at high bleeding risk (only BMS): TOAT for four weeks. After this initial period, up to 12 months with OAC with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 American College of Chest Physicians guideline on Antithrombotic therapy for atrial fibrillation makes the following recommendations (for each of these,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    alone is preferred after 12 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/31/13818/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For AF patients with a CHADS2 score &ge;2 (",
"      <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"       table 4",
"      </a>",
"      ), TOAT is recommended for one month after placement of a BMS and for three to six months after placement of a DES. After this initial period,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      plus a single antiplatelet drug is preferred to warfarin alone.",
"     </li>",
"     <li>",
"      For AF patients with a CHADS2 score of 0 or 1 who undergo stenting with either DES or BMS, dual antiplatelet therapy is preferred to TOAT.",
"     </li>",
"     <li>",
"      For AF patients with a CHADS2 score &ge;1 with an ACS but do not undergo stenting,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      plus single antiplatelet therapy for 12 months is preferred to TOAT or dual antiplatelet therapy. For these patients with a CHADS2 score of 0, dual antiplatelet therapy is preferred to warfarin plus single antiplatelet therapy or TOAT, although they acknowledge that patients who place a high value on stroke reduction may reasonably prefer warfarin plus single antiplatelet therapy to dual antiplatelet therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triple oral antithrombotic therapy (TOAT) with dual antiplatelet therapy (DAT) and oral anticoagulant (OAC), compared to less intense antithrombotic therapy, improves cardiovascular outcomes in many coronary artery disease patients who have indications for both. However, TOAT is associated with more frequent episodes of bleeding than less aggressive antithrombotic therapies. The challenge to clinicians and their patients is to balance the benefits and risks of TOAT. Strategies to reduce the likelihood of bleeding, including appropriate dosing and duration of therapy, are discussed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are two broad indications for DAT in patients with coronary artery disease: coronary artery stenting (to prevent stent thrombosis) and after acute coronary syndrome (to prevent recurrent ischemic events). Thus, the recommendations below are specific to the indication for DAT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For stented patients who have indications for both DAT and OAC, we suggest TOAT, as opposed to any other antithrombotic strategy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'TOAT versus OAC plus a single antiplatelet agent'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients at very high bleeding risk may consider omitting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      during the period of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      use based on the results of the WOEST trial. (See",
"      <a class=\"local\" href=\"#H66050976\">",
"       'Risk'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients at low-thromboembolic risk, such as patients with atrial fibrillation with a CHADS2 score of less than 2, may consider omitting OAC during the period of DAT. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'TOAT versus other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For stented patients taking dual antiplatelet therapy who require initiation of OAC to decrease the risk of embolization due to atrial fibrillation, we suggest either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      110 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      5 mg (both twice daily) in preference to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Issues of cost and availability may reasonably lead to a decision to start warfarin. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Alternatives to warfarin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For stented patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      to decrease the risk of embolization due to atrial fibrillation who need to be started on dual antiplatelet therapy, we suggest continuing warfarin as opposed to switching to any other oral anticoagulant (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients whose INR has been difficult to control, or who are at increased risk of bleeding for reasons other than TOAT, may reasonably be switched to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      110 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      5 mg (both twice daily). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Alternatives to warfarin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For stented patients who will require TOAT, and in whom the risk of restenosis is not excessive, we suggest bare-metal stents as opposed to drug-eluting stents in an attempt to shorten the duration of triple therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'DES versus BMS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those patients who will receive TOAT, we prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      as opposed to any other P2Y12 receptor blocker. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Alternatives to clopidogrel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of DAT in stented patients treated with TOAT is unknown. We agree with the approach recommended by the American College of Chest Physicians for choosing the duration of TOAT (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Major society guidelines'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The dose of the administered antithrombotic drugs should be minimized. We suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      be given at a daily dose of less than or equal to 100 mg and that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      be given at a daily dose of 75 mg. For patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , reasonable targets are international normalized ratios (INR) of 2.5 to 3.0 for patients with mechanical valves and 2.0 to 2.5 for patients with other indications. To maintain the INR at the narrower level, laboratory testing of INR should be performed more often than is commonly recommended. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management of anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated with either a drug-eluting or a bare metal stent who have a long-term indication for oral anticoagulant therapy, we suggest continuing low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      indefinitely after 12 months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who have received a bare-metal stent, OAC alone may be a reasonable alternative, particularly if the risk of bleeding is increased.",
"     </li>",
"     <li>",
"      For acute coronary syndrome patients who did not receive stenting and who require oral anticoagulant therapy, we suggest OAC plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      instead of TOAT for one year (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For these patients who are at low risk of bleeding (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1258?source=see_link&amp;anchor=H10#H10\">",
"       \"Anticoagulation in older adults\", section on 'Risk of bleeding'",
"      </a>",
"      ) and who are particularly concerned about recurrent ischemic events, TOAT is a reasonable option.",
"      <br/>",
"      <br/>",
"      For these patients who have not received an intracoronary stent and who have an indication for long-term oral anticoagulant therapy, we suggest not continuing aspirin (or other antiplatelet therapy) after one year (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Long-term antithrombotic therapy after TOAT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28163793\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Albert Schomig for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/1\">",
"      Sch&ouml;mig A, Sarafoff N, Seyfarth M. Triple antithrombotic management after stent implantation: when and how? Heart 2009; 95:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/2\">",
"      Holmes DR Jr, Kereiakes DJ, Kleiman NS, et al. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 2009; 54:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/3\">",
"      Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/4\">",
"      Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/5\">",
"      Ruiz-Nodar JM, Mar&iacute;n F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/6\">",
"      Ruiz-Nodar JM, Mar&iacute;n F, S&aacute;nchez-Pay&aacute; J, et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 2009; 30:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/7\">",
"      Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/8\">",
"      Sarafoff N, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 2008; 264:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/9\">",
"      Sambola A, Ferreira-Gonz&aacute;lez I, Angel J, et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart 2009; 95:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/10\">",
"      Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/11\">",
"      Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006; 130:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/12\">",
"      Wang TY, Robinson LA, Ou FS, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 2008; 155:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/13\">",
"      Porter A, Konstantino Y, Iakobishvili Z, et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2006; 68:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/14\">",
"      Hermosillo AJ, Spinler SA. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother 2008; 42:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/15\">",
"      Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006; 18:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/16\">",
"      Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004; 147:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/17\">",
"      S&oslash;rensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/18\">",
"      Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008; 40:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/19\">",
"      Nguyen MC, Lim YL, Walton A, et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007; 28:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/20\">",
"      Hansen ML, S&oslash;rensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/21\">",
"      Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/22\">",
"      Roy P, Bonello L, Torguson R, et al. Impact of \"nuisance\" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 2008; 102:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/23\">",
"      Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 2009; 30:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/24\">",
"      King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/25\">",
"      Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008; 102:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/26\">",
"      Hylek EM, Solarz DE. Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination. JACC Cardiovasc Interv 2008; 1:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/27\">",
"      Johnson SG, Rogers K, Delate T, Witt DM. Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 2008; 133:948.",
"     </a>",
"    </li>",
"    <li>",
"     Kastrati A. Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation (ISAR-TRIPLE), (NCT00776633) file://www.clinicaltrials.gov/ct2/show/NCT00776633?term=kastrati&amp;rank=12 (Accessed on December 01, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/29\">",
"      You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/30\">",
"      Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/31\">",
"      Sch&ouml;mig A. Ticagrelor--is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009; 361:1108.",
"     </a>",
"    </li>",
"    <li>",
"     file://spo.escardio.org/eslides/view.aspx?eevtid=48&amp;fp=1161 and file://spo.escardio.org/eslides/view.aspx?eevtid=48&amp;fp=1161.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/33\">",
"      Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/34\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/31/13818/abstract/35\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1535 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13818=[""].join("\n");
var outline_f13_31_13818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TOAT VERSUS OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TOAT versus DAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TOAT versus OAC plus a single antiplatelet agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22848168\">",
"      - After stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22848175\">",
"      - ACS patients treated medically",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Practice patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66050976\">",
"      Risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Outcomes after bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Management of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gastroprotective therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PERIPROCEDURAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Periprocedural bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DES versus BMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LONG-TERM ANTITHROMBOTIC THERAPY AFTER TOAT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NEWER ANTITHROMBOTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Alternatives to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Alternatives to warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28163793\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1535\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1535|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/14/39148\" title=\"table 1\">",
"      HAS-BLED risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/0/28684\" title=\"table 2\">",
"      Definitions major bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/37/11869\" title=\"table 3\">",
"      BARC definition for bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/45/40668\" title=\"table 4\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1258?source=related_link\">",
"      Anticoagulation in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20425?source=related_link\">",
"      Chronic anticoagulation after acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=related_link\">",
"      Outpatient management of oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=related_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=related_link\">",
"      Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=related_link\">",
"      Periprocedural bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_31_13819="Resection types sarcoma MSTS";
var content_f13_31_13819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of resection for sarcomas, Musculoskeletal Tumor Society",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Term",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radical resection",
"       </td>",
"       <td>",
"        Whole tumor-bearing compartment removed en bloc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wide resection",
"       </td>",
"       <td>",
"        Tumor and its pseudocapsule removed en bloc surrounded by",
"healthy tissue within the tumor-bearing compartment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marginal resection",
"       </td>",
"       <td>",
"        Tumor is removed en bloc; however, the line of resection runs",
"through the pseudocapsule of the tumor; microscopic residual disease",
"likely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intralesional resection",
"       </td>",
"       <td>",
"        Tumor opened during surgery, surgical field contaminated;",
"microscopic or macroscopic residual disease is present",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Data from: Enneking WF, Spanier SS, Malawer MM. The effect of the anatomic setting on the results of surgical procedures for soft parts sarcoma of the thigh. Cancer 1981; 47:1005.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13819=[""].join("\n");
var outline_f13_31_13819=null;
var title_f13_31_13820="Supplies for skin biopsy";
var content_f13_31_13820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Supplies for skin biopsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Isopropyl alcohol, povidone-iodine, or chlorhexadine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile gauze, 3x3 or 4x4, and sterile cotton-tip",
"applicators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cloth or plastic fenestrated drape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringes, 1 and 3 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Needles, 22-gauge (to draw up solutions), 30-gauge (for",
"injection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine, 1 or 2 percent, with and without",
"epinephrine. May buffer with 1 part NaHCO3 to 9 parts lidocaine, but",
"must be refrigerated and disposed after 30 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disposable surgical blades, 15 or 15c",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disposable punches, 4, 6, and 8 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Double-edge razor blade cut in half",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small tissue forceps (Adson 4 3/4 inch, 1x2 teeth, 1 mm",
"tip)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small tissue scissors (Grade 3 3/4 inch or tenotomy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Needle holders, 4 1/2 or 5 inch, smooth jaws, small tip",
"(Webster 4 1/2 inch). Consider purchase of disposable suture kits with",
"needle holders, forceps, and scissors included.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 percent aluminum chloride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-0 or 5-0 Nylon on C-17 or P-3 needles (4-0 for scalp)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Packaged alcohol swabs or tissues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibiotic ointment or plain petrolatum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spot and rectangular Band-Aid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonadherent dressings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paper tape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elastic wrap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 percent formalin specimen bottle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical marking pen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pathology request forms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient instructions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Alguire, PC, Mathes, BM, J Gen Intern Med 1998; 13:46.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13820=[""].join("\n");
var outline_f13_31_13820=null;
var title_f13_31_13821="Contraindications air travel";
var content_f13_31_13821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications to commercial air travel",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncomplicated myocardial infarction or PCI within past two to three weeks for most patients (unless very low risk: age &lt;65 years, ejection fraction &gt;45 percent, no symptoms of angina or heart failure; such patients may fly after three days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complicated myocardial infarction within past six weeks, or until stable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CABG within past two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe decompensated heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled severe or symptomatic hypertension*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe, symptomatic valvular heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke within past two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumothorax with persistent air leak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe, unstable asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe, unstable COPD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Major hemoptysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Usual oxygen requirement at sea level exceeds 4 L/minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post 36 to 37 weeks gestation (or medical certification done by an obstetrician may be required, at airline discretion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms consistent with ectopic pregnancy (eg, first trimester bleeding and/or abdominal pain) until evaluated by physician",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women at increased risk for complications during pregnancy should probably not fly (see text for details)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active or contagious infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nasal and sinus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large obstructing polyps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal or facial surgery within one to two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe, recurrent epistaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procedure-dependent: generally discouraged within two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncomplicated, simple laparoscopy or uncomplicated colonoscopy with polypectomy within two days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        SCUBA diving",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single, uncomplicated dive within 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple dives or dive requiring &gt;1 decompression stop within two days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychiatric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric disorders that predispose to violent, disruptive, unsafe, or unpredictable behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk for alcohol or drug withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ophthalmologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinal detachment surgery with gas bubble (two weeks for sulfur hexafluoride; six weeks for perfluoropropane)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCI: percutaneous coronary intervention; COPD: chronic obstructive pulmonary disease; CABG: coronary artery bypass graft.",
"     <br/>",
"     * There are no evidence-based parameters. Some experts suggest not flying for patients with blood pressure &gt;200/110 or malignant hypertension.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     If dive computer available, follow recommended parameters.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Medical Guidelines Task Force Aerospace Medical Association: Medical guidelines for airline travel, 2nd ed, Aviat Space Environ Med 2003; 74:A1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13821=[""].join("\n");
var outline_f13_31_13821=null;
var title_f13_31_13822="Clinical manifestations of sarcoidosis in different groups";
var content_f13_31_13822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of sarcoidosis in different groups",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of proportion of organ involvement in which there was a significant difference between groups on the basis of race, sex, or age.",
"    <div class=\"footnotes\">",
"     * Other than erythema nodosum.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baughman, RP, Teirstein, AS, Judson, MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885. Official Journal of the American Thoracic Society. Copyright &copy; 2001 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13822=[""].join("\n");
var outline_f13_31_13822=null;
var title_f13_31_13823="Comminuted metacarpal head fractures";
var content_f13_31_13823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comminuted metacarpal head fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal appearance of the 2nd metacarpal head can be compared to the comminuted fractures of the 3rd (arrow) and 4th (arrowhead) metacarpal heads. There is also proximal displacement of two of the fragments of the 3rd metacarpal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_31_13823=[""].join("\n");
var outline_f13_31_13823=null;
